Bortezomib (PS-341)

Name: Bortezomib (PS-341)
Brand: Selleck Chemicals
SKU: S1013
Rating: 5 (648 reviews)

For research use only.

Catalog No.S1013 Synonyms: LDP-341, MLM341

648 publications

CAS No. 179324-69-7

Bortezomib (PS-341, LDP-341, MLM341) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

Selleck's Bortezomib (PS-341) has been cited by 648 publications

Science, 2020, eabd0811

PubMed: 33243852 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 7;26(5):755-765 e7

PubMed: 32386556 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Science, 2019, 363(6429)

PubMed: 30792274 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2018, 560(7718):325-330

PubMed: 30089904 ( click the link to review the publication )

Nat Med, 2018, 24(4):497-504

PubMed: 29457796 ( click the link to review the publication )

Nat Med, 2018, 24(3):292-303

PubMed: 29400713 ( click the link to review the publication )

Nature, 2017, 550(7677):534-538

PubMed: 29045385 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell, 2017, 171(5):1094-1109

PubMed: 29149604 ( click the link to review the publication )

Nat Med, 2017, 23(9):1055-1062

PubMed: 28805822 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):748-760

PubMed: 29232553 ( click the link to review the publication )

Nat Med, 2014, 20(6):599-606

PubMed: 24813251 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):242-52

PubMed: 22862949 ( click the link to review the publication )

Blood, 2020, 18 pii: blood

PubMed: 32187357 ( click the link to review the publication )

Mol Cell, 2020, 5;77(5):1092-1106 e9

PubMed: 31973889 ( click the link to review the publication )
Nat Commun, 2020, 22;11(1):1931

PubMed: 32321912 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2020.1740529

PubMed: 32164484 ( click the link to review the publication )

Autophagy, 2020, 18;1-13

PubMed: 32186434 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-01034-y

PubMed: 32879426 ( click the link to review the publication )

Leukemia, 2020, 18

PubMed: 32424294 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )

Clin Cancer Res, 2020, 27 pii: clincanres

PubMed: 32341033 ( click the link to review the publication )

Theranostics, 2020, 10(8):3366-3381

PubMed: 32206096 ( click the link to review the publication )

Blood Cancer J, 2020, 10(12):125

PubMed: 33318477 ( click the link to review the publication )

Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Rep, 2020, 3;30(9):2948-2962 e4

PubMed: 32130899 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00649-z

PubMed: 33110214 ( click the link to review the publication )

Redox Biol, 2020, 20;101465

PubMed: 32473993 ( click the link to review the publication )

Oncogene, 2020, 9

PubMed: 32388539 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1183-x

PubMed: 32034308 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03568-x

PubMed: 32607595 ( click the link to review the publication )

Sci Signal, 2020, 13(649)eaba5665

PubMed: 32934076 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3335

PubMed: 33187254 ( click the link to review the publication )

Cancers (Basel), 2020, 30;12(4):831

PubMed: 32235588 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Cancers (Basel), 2020, 11;12(5):E1207

PubMed: 32403415 ( click the link to review the publication )
PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):796

PubMed: 32968046 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):701

PubMed: 32839432 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):783

PubMed: 32951004 ( click the link to review the publication )

J Clin Med, 2020, 9(2)

PubMed: 32085480 ( click the link to review the publication )

Cells, 2020, 9(11)E2357

PubMed: 33114738 ( click the link to review the publication )

FASEB J, 2020, 34(9):12379-12391

PubMed: 32960474 ( click the link to review the publication )

Cell Chem Biol, 2020, 18 pii: S2451-9456(20)30117-3

PubMed: 32386596 ( click the link to review the publication )

Pain, 2020, 161(1):177-184

PubMed: 31490328 ( click the link to review the publication )

Front Immunol, 2020,

PubMed: 32903557 ( click the link to review the publication )

Oncoimmunology, 2020, 9(1):1831153

PubMed: 33110706 ( click the link to review the publication )

Curr Biol, 2020, S0960-9822(20)31156-8

PubMed: 32857970 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12853

PubMed: 33188726 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:44

PubMed: 32117974 ( click the link to review the publication )

Aging (Albany NY), 2020, 16;12(8):6611-6629

PubMed: 32298237 ( click the link to review the publication )

Respirology, 2020, 10.1111/resp.13867

PubMed: 32512637 ( click the link to review the publication )

Cancer Sci, 2020, 111(4):1279-1290

PubMed: 32058648 ( click the link to review the publication )

J Immunol, 2020, 205(10):2583-2594

PubMed: 33067378 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15675

PubMed: 33340237 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(12)E1300

PubMed: 33353055 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:117

PubMed: 32117764 ( click the link to review the publication )

J Cell Sci, 2020, jcs.241356

PubMed: 32546533 ( click the link to review the publication )

J Virol, 2020, 6;94(2) pii: e01173-19

PubMed: 31619561 ( click the link to review the publication )
J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E7905

PubMed: 33114380 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5562

PubMed: 32221318 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015398

PubMed: 33082144 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00544-w

PubMed: 33139838 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Mol Cell Biol, 2020, MCB.00269-20

PubMed: 33168699 ( click the link to review the publication )

Cell Cycle, 2020, 19;1-12

PubMed: 32423265 ( click the link to review the publication )

Int J Biochem Cell Biol, 2020, 122:105734

PubMed: 32119989 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Mol Cells, 2020, 31;43(1):23-33

PubMed: 31870133 ( click the link to review the publication )

Eur J Pharmacol, 2020, 875:173050

PubMed: 32142770 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1661-1672

PubMed: 32236619 ( click the link to review the publication )

Saudi J Biol Sci, 2020, 27(8):2157-2163

PubMed: 32714042 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0232068

PubMed: 32559187 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 8;521(2):414-419

PubMed: 31672277 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Technol Cancer Res Treat, 2020, 19:1533033820948060

PubMed: 32924793 ( click the link to review the publication )
Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Hematology, 2020, 25(1):424-432

PubMed: 33191863 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.227215

PubMed: 31919082 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.1232.2020

PubMed: 32669378 ( click the link to review the publication )

EMBO Mol Med, 2020, e11793

PubMed: 32720440 ( click the link to review the publication )

Cancer Rep (Hoboken), 2020, e1267

PubMed: 32706923 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Oncotarget, 2020, 11(7):727-739

PubMed: 32133047 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):89

PubMed: 32653014 ( click the link to review the publication )

RNA Biol, 2020, 10.1080/15476286.2020.1813439

PubMed: 32819190 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cells, 2020, 43(11):935-944

PubMed: 33168788 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2020, 48(1):735-745

PubMed: 32272856 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12853

PubMed: 33188726 ( click the link to review the publication )

J Leukoc Biol, 2020, 107(1):105-112

PubMed: 31729784 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202009137

PubMed: 32788348 ( click the link to review the publication )

Cancer Lett, 2020, 475:99-108

PubMed: 32014459 ( click the link to review the publication )

Nat Metab, 2020, 10.1038/s42255-020-0252-3

PubMed: 32778834 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2341

PubMed: 32825035 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Autophagy, 2020, 1-17

PubMed: 32762399 ( click the link to review the publication )
J Virol, 2020, JVI.01604-20

PubMed: 32817219 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

Hematology, 2020, 25(1):424-432

PubMed: 33191863 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15480

PubMed: 32648994 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Gastroenterology, 2019, 157(6):1615-1629

PubMed: 31446059 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.31059

PubMed: 31808574 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):273

PubMed: 30655516 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4184

PubMed: 31519875 ( click the link to review the publication )

Sci Adv, 2019, 5(2):eaau7130

PubMed: 30775435 ( click the link to review the publication )

Autophagy, 2019, 15(11):1954-1969

PubMed: 30894069 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1635380

PubMed: 31242129 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Leukemia, 2019, 33(1):171-180

PubMed: 30026574 ( click the link to review the publication )

Dev Cell, 2019, 50(1):11-24.e10

PubMed: 31130353 ( click the link to review the publication )

Dev Cell, 2019, 50(6):690-703.e6

PubMed: 31378590 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2200-2209

PubMed: 30674681 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31138526 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.212266

PubMed: 31101754 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):28

PubMed: 30717817 ( click the link to review the publication )
Kidney Int, 2019, 95(3):611-623

PubMed: 30685098 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31142515 ( click the link to review the publication )

Cancer Res, 2019, 79(21):5536-5549

PubMed: 31530568 ( click the link to review the publication )

Cell Rep, 2019, 27(6):1657-1665

PubMed: 31067453 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1249-1260

PubMed: 31665637 ( click the link to review the publication )

J Control Release, 2019, 306:149-164

PubMed: 31121280 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Elife, 2019, 8e44161

PubMed: 30860482 ( click the link to review the publication )

Elife, 2019, 8e48469

PubMed: 31516121 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.45457

PubMed: 30907729 ( click the link to review the publication )

Haematologica, 2019, 103324/haematol2019216986

PubMed: 31123029 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32615

PubMed: 31390487 ( click the link to review the publication )

Oncogene, 2019, 38(16):3047-3060

PubMed: 30617306 ( click the link to review the publication )

mBio, 2019, 10(2)e00668-19

PubMed: 31015330 ( click the link to review the publication )

mBio, 2019, 10(3)

PubMed: 31088925 ( click the link to review the publication )

Am J Transplant, 2019, 19(3):724-736

PubMed: 30102844 ( click the link to review the publication )

Cancer Lett, 2019, 442:233-241

PubMed: 30419344 ( click the link to review the publication )

J Med Chem, 2019, 62(15):7042-7057

PubMed: 31271281 ( click the link to review the publication )

Cancers (Basel), 2019, 11(7)

PubMed: 31315220 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31756922 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E85

PubMed: 30646520 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)E236

PubMed: 30781685 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31466401 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31771104 ( click the link to review the publication )
PLoS Pathog, 2019, 15(1):e1007498

PubMed: 30645648 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):781

PubMed: 31611552 ( click the link to review the publication )

Cell Death Discov, 2019, 5:131

PubMed: 31482012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.006

PubMed: 31303577 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(11):1544-1558.e6

PubMed: 31522999 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):340-351

PubMed: 30612952 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(6):999-1014

PubMed: 31838790 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(7):1205-1216

PubMed: 31092565 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-18-1319

PubMed: 31594826 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(11):3624-3638

PubMed: 31170093 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(3):1653-1664

PubMed: 29916141 ( click the link to review the publication )

Neoplasia, 2019, 21(7):653-664

PubMed: 31132676 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:1659468

PubMed: 31281566 ( click the link to review the publication )

ACS Infect Dis, 2019, 5(12):2105-2117

PubMed: 31644867 ( click the link to review the publication )

Eur J Med Chem, 2019, 166:65-74

PubMed: 30684871 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1622-1634

PubMed: 31497346 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1544-1555

PubMed: 31326539 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):252-263

PubMed: 30445147 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31540997 ( click the link to review the publication )
ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

J Immunol, 2019, 202(10):2849-2855

PubMed: 30936292 ( click the link to review the publication )

Mol Cancer Res, 2019,

PubMed: 31409628 ( click the link to review the publication )

Front Oncol, 2019, 9:958

PubMed: 31632904 ( click the link to review the publication )

Front Oncol, 2019, 9:722

PubMed: 31440466 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(8):5390-5402

PubMed: 31140729 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(7):838-850

PubMed: 30865564 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(9)

PubMed: 31307977 ( click the link to review the publication )

Talanta, 2019, 199:32-39

PubMed: 30952265 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(20)

PubMed: 31635163 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30736330 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)

PubMed: 31817163 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7901

PubMed: 31133683 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2443

PubMed: 30792442 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6915

PubMed: 31061434 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Sci Rep, 2019, 9(1):14394

PubMed: 31591429 ( click the link to review the publication )

Sci Rep, 2019, 9(1):18409

PubMed: 31804603 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7199

PubMed: 31076590 ( click the link to review the publication )

Sci Rep, 2019, 9(1):18062

PubMed: 31792264 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(40):14562-14573

PubMed: 31371451 ( click the link to review the publication )
J Biol Chem, 2019,

PubMed: 30523157 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Gene, 2019, 707:86-92

PubMed: 31071385 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:8711-8720

PubMed: 31576173 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )

Int J Oncol, 2019, 55(2):499-512

PubMed: 31268156 ( click the link to review the publication )

Cell Signal, 2019, 59:76-84

PubMed: 30878517 ( click the link to review the publication )

Cell Signal, 2019, 62:109351

PubMed: 31260799 ( click the link to review the publication )

J Cell Biochem, 2019, 120(3):3243-3258

PubMed: 30362618 ( click the link to review the publication )

Am J Transl Res, 2019, 11(7):4139-4150

PubMed: 31396324 ( click the link to review the publication )

Biochimie, 2019, 162:46-54

PubMed: 30946948 ( click the link to review the publication )

Molecules, 2019, 24(5)

PubMed: 30818834 ( click the link to review the publication )

Oncol Rep, 2019, 42(1):35-42

PubMed: 31115546 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1678-1690

PubMed: 30664164 ( click the link to review the publication )

ChemMedChem, 2019, 14(23):2005-2022

PubMed: 31675179 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0225145

PubMed: 31703099 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1140-1146

PubMed: 31103265 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:11383-11391

PubMed: 31920329 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1616190

PubMed: 31111763 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(4):461-466

PubMed: 30554340 ( click the link to review the publication )
Methods Enzymol, 2019, 619:145-159

PubMed: 30910019 ( click the link to review the publication )

Iran J Pharm Res, 2019, 18(Suppl1):119-131

PubMed: 32802093 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3167-3181.e6

PubMed: 31533039 ( click the link to review the publication )

J Blood Med, 2019, 10:105-109

PubMed: 31043801 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2709-2721

PubMed: 31105871 ( click the link to review the publication )

Oncotarget, 2019, 10(63):6781-6790

PubMed: 31827721 ( click the link to review the publication )

Toxicol Forensic Med, 2019, 4(1):13-17

PubMed: 32149269 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2019, 1863(6):1108-1115

PubMed: 30974160 ( click the link to review the publication )

Blood Adv, 2019, 3(1):51-62

PubMed: 30617217 ( click the link to review the publication )

Mol Cell, 2018, 70(5):906-919

PubMed: 29804830 ( click the link to review the publication )

Mol Cell, 2018, 72(5):862-874

PubMed: 30318442 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4682-4696

PubMed: 30198908 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):502

PubMed: 29402884 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4514

PubMed: 30375513 ( click the link to review the publication )

Nat Commun, 2018, 9(1):672

PubMed: 29445180 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6408-6420

PubMed: 30126942 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Theranostics, 2018, 8(9):2348-2360

PubMed: 29721084 ( click the link to review the publication )

Kidney Int, 2018, 93(3):670-680

PubMed: 29229189 ( click the link to review the publication )
Blood Cancer J, 2018, 8(11):105

PubMed: 30409995 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):29

PubMed: 29482577 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(33):4581-4598

PubMed: 29748621 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 420:156-167

PubMed: 29410067 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2018, 38(11):1924-1939

PubMed: 29972341 ( click the link to review the publication )

PLoS Genet, 2018, 14(1):e1007165

PubMed: 29370161 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):1871-1880

PubMed: 29959200 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Mol Oncol, 2018, 12(12):2124-2135

PubMed: 30259640 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):75

PubMed: 30250021 ( click the link to review the publication )

J Cell Physiol, 2018, 233(5):4258-4271

PubMed: 29057477 ( click the link to review the publication )

J Cell Sci, 2018, 131(14)jcs216671

PubMed: 29930081 ( click the link to review the publication )

Lab Invest, 2018, 98(6):708-714

PubMed: 29540860 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:291-301

PubMed: 30149015 ( click the link to review the publication )

Sci Rep, 2018, 8(1):671

PubMed: 29330435 ( click the link to review the publication )

J Biol Chem, 2018, 293(4):1178-1191

PubMed: 29183995 ( click the link to review the publication )

J Biol Chem, 2018, 293(7):2452-2465

PubMed: 29279332 ( click the link to review the publication )
Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

J Ethnopharmacol, 2018, 220:220-227

PubMed: 29097252 ( click the link to review the publication )

Exp Cell Res, 2018, 371(2):353-363

PubMed: 30149001 ( click the link to review the publication )

Exp Cell Res, 2018, 369(1):120-128

PubMed: 29772221 ( click the link to review the publication )

J Mol Endocrinol, 2018, 60(2):45-54

PubMed: 29191827 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):432

PubMed: 29661248 ( click the link to review the publication )

Int Immunopharmacol, 2018, 54:39-45

PubMed: 29100036 ( click the link to review the publication )

Molecules, 2018, 23(12)

PubMed: 30567313 ( click the link to review the publication )

Mol Cells, 2018, 41(12):1008-1015

PubMed: 30396235 ( click the link to review the publication )

Oncol Rep, 2018, 39(6):2873-2880

PubMed: 29693175 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3714-3724

PubMed: 30272343 ( click the link to review the publication )

Eur J Pharmacol, 2018, 830:17-25

PubMed: 29680228 ( click the link to review the publication )

Oncol Res, 2018, 26(3):421-429

PubMed: 28899456 ( click the link to review the publication )

Biosci Rep, 2018, 38(5)

PubMed: 30177525 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 501(1):286-292

PubMed: 29729272 ( click the link to review the publication )

G3 (Bethesda), 2018, 8(7):2193-2204

PubMed: 29735526 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 505(1):126-133

PubMed: 30236985 ( click the link to review the publication )

J Bone Miner Metab, 2018, 36(5):537-546

PubMed: 29027021 ( click the link to review the publication )

Ann Diagn Pathol, 2018, 32:28-34

PubMed: 29414394 ( click the link to review the publication )

Target Oncol, 2018, 13(6):779-793

PubMed: 30446871 ( click the link to review the publication )

J Exp Med, 2018, 215(5):1301-1313

PubMed: 29703731 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29423101 ( click the link to review the publication )

Oncotarget, 2018, 9(23):16521-16532

PubMed: 29662664 ( click the link to review the publication )
Viruses, 2018, 10(10)

PubMed: 30261679 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:291-301

PubMed: 30149015 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29861856 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Blood, 2017, 5;129(1):88-99

PubMed: 27784673 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1692

PubMed: 29167449 ( click the link to review the publication )

Nat Commun, 2017, 8:15244

PubMed: 28489076 ( click the link to review the publication )

Nat Commun, 2017, 8:15676

PubMed: 28607490 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1391

PubMed: 29123089 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):1012-1024

PubMed: 28151717 ( click the link to review the publication )

Leukemia, 2017, 31(7):1570-1581

PubMed: 27890927 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(10):839-846

PubMed: 28903971 ( click the link to review the publication )

Cancer Res, 2017, 77(22):6282-6298

PubMed: 28978635 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2927-2937

PubMed: 28404587 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Genomics Inform, 2017, 15(3):87-97

PubMed: 29020724 ( click the link to review the publication )

Cancer Lett, 2017, 405:63-72

PubMed: 28716527 ( click the link to review the publication )

J Pathol, 2017, 241(4):534-546

PubMed: 27976373 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2585

PubMed: 28151478 ( click the link to review the publication )

Exp Mol Med, 2017, 49(8):e365

PubMed: 28798402 ( click the link to review the publication )
Mol Cancer Ther, 2017,

PubMed: 28108597 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2375-2386

PubMed: 28878026 ( click the link to review the publication )

Br J Haematol, 2017, 179(5):756-771

PubMed: 29048129 ( click the link to review the publication )

J Cancer, 2017, 8(5):839-851

PubMed: 28382147 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Biochem Pharmacol, 2017, 143:118-128

PubMed: 28642038 ( click the link to review the publication )

Sci Rep, 2017, 7:44700

PubMed: 28304377 ( click the link to review the publication )

Am J Pathol, 2017, 187(12):2775-2787

PubMed: 28919113 ( click the link to review the publication )

J Biol Chem, 2017, 292(28):11970-11979

PubMed: 28588027 ( click the link to review the publication )

Endocrinology, 2017, 158(4):1005-1014

PubMed: 28323983 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3097-3108

PubMed: 28938421 ( click the link to review the publication )

Biomed Pharmacother, 2017, 88:562-568

PubMed: 28131096 ( click the link to review the publication )

BMC Genomics, 2017, 18(1):127

PubMed: 28166733 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Cell Signal, 2017, 32:124-132

PubMed: 28161489 ( click the link to review the publication )

Mol Brain, 2017, 10(1):7

PubMed: 28196470 ( click the link to review the publication )

Life Sci, 2017, 173:36-42

PubMed: 28212825 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):366

PubMed: 28545541 ( click the link to review the publication )

Neurotox Res, 2017, 32(4):555-562

PubMed: 28612296 ( click the link to review the publication )

Transl Oncol, 2017, 10(4):632-640

PubMed: 28668761 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(2):400-406

PubMed: 28502636 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(12):2916-2925

PubMed: 28509582 ( click the link to review the publication )

Cancer Genomics Proteomics, 2017, 14(1):35-51

PubMed: 28031236 ( click the link to review the publication )

Oncol Lett, 2017, 13(2):647-654

PubMed: 28356941 ( click the link to review the publication )
Cancer Metab, 2017, 5:7

PubMed: 28855983 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114698-114709

PubMed: 29383113 ( click the link to review the publication )

Oncotarget, 2017, 9(3):2984-3000

PubMed: 29423023 ( click the link to review the publication )

Cell, 2017, 170(5):860-874

PubMed: 28803730 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114698-114709

PubMed: 29383113 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80109-80123

PubMed: 29113288 ( click the link to review the publication )

Cell, 2017, 169(6):1105-1118

PubMed: 28575672 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Hepatology, 2017, 66(3):855-868

PubMed: 28439950 ( click the link to review the publication )

Sci Rep, 2017, 7(1):682

PubMed: 28386133 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56243-56254

PubMed: 28915587 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52445-52456

PubMed: 28881742 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):202-12

PubMed: 26655835 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra70

PubMed: 27194728 ( click the link to review the publication )

Hepatology, 2016, 64(1):161-74

PubMed: 26926206 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:12368

PubMed: 27492902 ( click the link to review the publication )

Nat Commun, 2016, 7:13150

PubMed: 27748395 ( click the link to review the publication )

Autophagy, 2016, 12(4):632-47

PubMed: 27050454 ( click the link to review the publication )

EMBO J, 2016, 35(23):2602-2613

PubMed: 27789522 ( click the link to review the publication )

Leukemia, 2016, 30(4):861-72

PubMed: 26658839 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(46):13162-13167

PubMed: 27799547 ( click the link to review the publication )
Genes Dev, 2016, 30(24):2684-2695

PubMed: 28087713 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3531-40

PubMed: 27197154 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1222-33

PubMed: 26527748 ( click the link to review the publication )

Plant Cell, 2016, 28(6):1279-96

PubMed: 27194708 ( click the link to review the publication )

Matrix Biol, 2016, 55:22-34

PubMed: 27016342 ( click the link to review the publication )

Blood Cancer J, 2016, 6(8):e462

PubMed: 27564460 ( click the link to review the publication )

Blood Cancer J, 2016, 6(7):e446

PubMed: 27421095 ( click the link to review the publication )

Cell Rep, 2016, 16(1):120-132

PubMed: 27320908 ( click the link to review the publication )

Oncogene, 2016, 35(38):4973-80

PubMed: 26973240 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):82-8

PubMed: 26721204 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005929

PubMed: 27706223 ( click the link to review the publication )

Lab Chip, 2016, 16(2):334-44

PubMed: 26660268 ( click the link to review the publication )

J Neurosci, 2016, 36(6):1930-41

PubMed: 26865616 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2492

PubMed: 27906188 ( click the link to review the publication )

FASEB J, 2016, 30(2):923-32

PubMed: 26546130 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(8):1075-81

PubMed: 27087021 ( click the link to review the publication )

Br J Haematol, 2016, 173(1):70-81

PubMed: 26729247 ( click the link to review the publication )

Dis Model Mech, 2016, 9(11):1317-1328

PubMed: 27519691 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(8):1272-85

PubMed: 26941331 ( click the link to review the publication )

Am J Pathol, 2016, 186(3):678-90

PubMed: 26801735 ( click the link to review the publication )

J Biol Chem, 2016, 291(45):23719-23733

PubMed: 27621311 ( click the link to review the publication )

J Biol Chem, 2016, 291(2):939-47

PubMed: 26527686 ( click the link to review the publication )

J Biol Chem, 2016, 291(29):15082-92

PubMed: 27226596 ( click the link to review the publication )
Int J Oncol, 2016, 49(5):1848-1858

PubMed: 27601063 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(9):966-75

PubMed: 27434731 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:99-104

PubMed: 27568836 ( click the link to review the publication )

Eur J Cell Biol, 2016, 95(10):389-400

PubMed: 27567537 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150044

PubMed: 26982031 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0168193

PubMed: 27978543 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150484

PubMed: 26930278 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(7):1677-86

PubMed: 26421357 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

Oncotarget, 2016, 7(25):38523-38538

PubMed: 27229530 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4062-76

PubMed: 26716651 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):751-60

PubMed: 27045812 ( click the link to review the publication )

Sarcoma, 2016, 2016:3484673

PubMed: 27822137 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Drug Discov Ther, 2016, 10(4):195-200

PubMed: 27594296 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71790-71801

PubMed: 27708243 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45214-45224

PubMed: 27286258 ( click the link to review the publication )
Oncotarget, 2016, 7(4):4559-69

PubMed: 26683226 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12254-66

PubMed: 26930721 ( click the link to review the publication )

Oncotarget, 2016, 7(43):70845-70856

PubMed: 27683126 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78883-78895

PubMed: 27713151 ( click the link to review the publication )

Oncotarget, 2016, 7(38):62572-62584

PubMed: 27613836 ( click the link to review the publication )

Mol Cells, 2016, 39(12):898-908

PubMed: 28008160 ( click the link to review the publication )

Sci Rep, 2016, 6:28528

PubMed: 27339427 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(7):917-29

PubMed: 26075355 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1462

PubMed: 25748087 ( click the link to review the publication )

Leukemia, 2015, 29(6):1390-401

PubMed: 25533804 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2109

PubMed: 25712341 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4663-75

PubMed: 26116270 ( click the link to review the publication )

Biomaterials, 2015, 73:70-84

PubMed: 26402156 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 211:44-52

PubMed: 26031842 ( click the link to review the publication )

Elife, 2015, 4:e08153

PubMed: 26327694 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.455

PubMed: 25619841 ( click the link to review the publication )

Oncogene, 2015, 34(16):2138-2144

PubMed: 24909167 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

J Dent Res, 2015, 94(9):1243-50

PubMed: 26130255 ( click the link to review the publication )

Br J Haematol, 2015,

PubMed: 26310606 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-50

PubMed: 25973303 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )
J Immunol, 2015, 194(4):1695-701

PubMed: 25560410 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

Traffic, 2015, 10.1111/tra.12287

PubMed: 25824657 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: 25520503 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: ( click the link to review the publication )

Toxicol Sci, 2015, 10.1093/toxsci/kfv056

PubMed: 25766884 ( click the link to review the publication )

Sci Rep, 2015, 5:18251

PubMed: 26671574 ( click the link to review the publication )

Sci Rep, 2015, 5:13001

PubMed: 26306624 ( click the link to review the publication )

J Biol Chem, 2015, 290(50):29854-68

PubMed: 26483548 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-650

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 283(1):1-8

PubMed: 25576094 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: 25422130 ( click the link to review the publication )

Phys Chem Chem Phys, 2015, 17(29):18971-9

PubMed: 26126833 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:738

PubMed: 26483043 ( click the link to review the publication )

BMC Cancer, 2015, 15:444

PubMed: 26025442 ( click the link to review the publication )

Toxicol In Vitro, 2015, 29(8):1965-76

PubMed: 26165741 ( click the link to review the publication )

Biomed Rep, 2015, 3(6):797-801

PubMed: 26623018 ( click the link to review the publication )

Biosci Rep, 2015, 35(6)

PubMed: 26500282 ( click the link to review the publication )

Malar J, 2015, 14(1):200

PubMed: 25968882 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )
Biomed Res Int, 2015, 2015:417586

PubMed: 26539491 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Int J Hematol, 2015, 102(5):569-78

PubMed: 26341959 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

J Bio Mater Res, 2015, 103(4):1476-84

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(38):40704-18

PubMed: 26513019 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Chem Biol, 2015, 10.1016/j.chembiol.2015.01.004

PubMed: 25728267 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(10):8418-29

PubMed: 25762625 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Oncotarget, 2015, 6(28):26347-58

PubMed: 26267322 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38079-92

PubMed: 26472030 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )

Oncotarget, 2015, 6(17):14953-69

PubMed: 25879451 ( click the link to review the publication )

Sci Transl Med, 2014, 6(250):250ra112

PubMed: 25143362 ( click the link to review the publication )

Blood, 2014, 20;124(22):3250-9

PubMed: 25205118 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(9):3757-66

PubMed: 25061876 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Nat Commun, 2014, 5:3772

PubMed: 24805825 ( click the link to review the publication )

Autophagy, 2014, 10(9):1603-21

PubMed: 25046115 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(16):E1591-9

PubMed: 24715725 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2803-15

PubMed: 24686171 ( click the link to review the publication )

Cancer Res, 2014, 74(11):3127-36

PubMed: 24755468 ( click the link to review the publication )

J Cell Biol, 2014, 205(6):771-80

PubMed: 24934156 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1838-51

PubMed: 25034784 ( click the link to review the publication )

Mol Cancer, 2014, 13(1):159

PubMed: 24972933 ( click the link to review the publication )

Int J Cancer, 2014, 135(12):2950-61

PubMed: 24771510 ( click the link to review the publication )

Eur J Cancer, 2014, 51(1):1-8

PubMed: 25466507 ( click the link to review the publication )

Cancer Lett, 2014, 343(2):286-94

PubMed: 24120758 ( click the link to review the publication )

Br J Cancer, 2014, 110(9):2224-31

PubMed: 24691427 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1126

PubMed: 24625985 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1580

PubMed: 25522274 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):3013-23

PubMed: 25253782 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )

J Nutr Biochem, 2014, 25(5):515-25

PubMed: 24613086 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt13):2898-909

PubMed: 24806960 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 21):4728-39

PubMed: 25179605 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )
Eur J Immunol, 2014, 44(6):1604-14

PubMed: 24643698 ( click the link to review the publication )

J Leukocyte Biol, 2014, 95(3):461-9

PubMed: 24231258 ( click the link to review the publication )

Sci Rep, 2014, 4:4164

PubMed: 24566666 ( click the link to review the publication )

Sci Rep, 2014, 4:6370

PubMed: 25231679 ( click the link to review the publication )

Cancer Gene Ther, 2014, 21(11):472-82

PubMed: 25323693 ( click the link to review the publication )

J Biol Chem, 2014, 289(17):11906-15

PubMed: 24570003 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14075-88

PubMed: 24711452 ( click the link to review the publication )

J Biol Chem, 2014, 289(5):2687-700

PubMed: 24337575 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(19):3570-8

PubMed: 25022755 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(9):C774-87

PubMed: 25143351 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(10):1350-7

PubMed: 25019382 ( click the link to review the publication )

World J Gastroenterol, 2014, 20(48):18207-15

PubMed: 25561788 ( click the link to review the publication )

J Biomed Mater Res A, 2014, 10.1002/jbm.a.35286

PubMed: 25046528 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )

Neurotoxicology, 2014, 42:33-48

PubMed: 24705302 ( click the link to review the publication )

J Vasc Interv Radiol, 2014, 25(12):1972-82

PubMed: 25439675 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 73(1):69-77

PubMed: 24190701 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 10.1007/s00280-014-2451-7

PubMed: 24842158 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(6):e99211

PubMed: 24911872 ( click the link to review the publication )

PLoS One, 2014, 9(3):e89848

PubMed: 24595136 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107009

PubMed: 25255316 ( click the link to review the publication )

Mol Cell Biochem, 2014, 398(1-2):165-73

PubMed: 25292312 ( click the link to review the publication )
J Nanopart Res, 2014, 42:33-48

PubMed: http://link.springer.com/article/10.1007/s11051-01 ( click the link to review the publication )

Biosciences biotechnology research asia, 2014, 10.13005bbra.1309

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:5896

PubMed: 25077633 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Hepatology, 2013, 57(2):625-36

PubMed: 22991197 ( click the link to review the publication )

Nat Chem Biol, 2013, 10(1):61-8

PubMed: 24292069 ( click the link to review the publication )

Nat Protoc, 2013, 8(6):1155-68

PubMed: 23702832 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):3019-31

PubMed: 23584492 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(1):246-51

PubMed: 23248292 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(9):3501-6

PubMed: 23382202 ( click the link to review the publication )

Cancer Res, 2013, 74(1):56-67

PubMed: 24310398 ( click the link to review the publication )

Cell Rep, 2013, 4(4):751-63

PubMed: 23954782 ( click the link to review the publication )

Mucosal Immunol, 2013, 7(4):857-68

PubMed: 24280938 ( click the link to review the publication )

Int J Cancer, 2013, 133(6):1357-67

PubMed: 23463417 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(6):R107

PubMed: 24207099 ( click the link to review the publication )

Br J Dermatol, 2013, 168(3):504-12

PubMed: 23445313 ( click the link to review the publication )

Free Rad Biol Med, 2013, 65:778-88

PubMed: 23973637 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e50

PubMed: 24158003 ( click the link to review the publication )

Pain, 2013, 154(11):2432-40

PubMed: 23891899 ( click the link to review the publication )

Expert Opin Drug Deliv, 2013, 10(10):1345-52

PubMed: 23937147 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1012-8

PubMed: 23916134 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(3):578-87

PubMed: 23198928 ( click the link to review the publication )
Gynecol Oncol, 2013, 128(2):383-90

PubMed: 23107612 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

J Virol, 2013, 87(21):11872-83

PubMed: 23986594 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(10):4456-69

PubMed: 23742826 ( click the link to review the publication )

Biochem Pharmacol, 2013, 85(11):1611-8

PubMed: 23523860 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

J Trauma Acute Care Surg, 2013, 74(2):499-507

PubMed: 23354244 ( click the link to review the publication )

Mol Biol Cell, 2013, 35:215-22

PubMed: 24145151 ( click the link to review the publication )

Clin Exp Metastasis, 2013, 30(4):407-15

PubMed: 23412907 ( click the link to review the publication )

Retrovirology, 2013, 10(1):120

PubMed: 24156270 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1551-62

PubMed: 23877657 ( click the link to review the publication )

Toxicol Lett, 2013, 223(2):109-15

PubMed: 24055520 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(6):1335-42

PubMed: 24121478 ( click the link to review the publication )

Chembiochem, 2013, 14(12):1494-503

PubMed: 23881799 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73710

PubMed: 24040035 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59390

PubMed: 23527180 ( click the link to review the publication )

PLoS One, 2013, 8(9):e75280

PubMed: 24086494 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82053

PubMed: 24312627 ( click the link to review the publication )

Eur J Haematol, 2013, 91(4):339-46

PubMed: 23869695 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1302-8

PubMed: 23896061 ( click the link to review the publication )

J Int Med Res, 2013, 41(5):1505-19

PubMed: 23975859 ( click the link to review the publication )

Curr Protoc Chem Biol, 2013, 5(3):195-212

PubMed: 24391083 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

Blood, 2012, 119(24):5772-81

PubMed: 22538852 ( click the link to review the publication )
Blood, 2012, 119(11):2579-89

PubMed: 22262760 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):387-94

PubMed: 22407014 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4669-81

PubMed: 22806876 ( click the link to review the publication )

Br J Pharmacol, 2012, 168(8):1868-77

PubMed: 23194305 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(5):1487-96

PubMed: 22377766 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e295

PubMed: 22495350 ( click the link to review the publication )

FASEB J, 2012, 26(5):1855-65

PubMed: 22345405 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(10):2243-53

PubMed: 22933706 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(18):10112-22

PubMed: 22787216 ( click the link to review the publication )

J Virol, 2012, 86(24):13360-70

PubMed: 23015717 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2012, 303(3):E410-21

PubMed: 22669242 ( click the link to review the publication )

J Biol Chem, 2012, 287(13):10344-54

PubMed: 22318734 ( click the link to review the publication )

J Biol Chem, 2012, 288(2):1125-34

PubMed: 23209294 ( click the link to review the publication )

J Biol Chem, 2012, 288(4):2721-33

PubMed: 23209292 ( click the link to review the publication )

J Biol Chem, 2012, 287(41):34722-9

PubMed: 22910913 ( click the link to review the publication )

J Pharmacol Exp Ther, 2012, 343(1):184-97

PubMed: 22787116 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Cell Cycle, 2012, 11(9):1804-17

PubMed: 22510564 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Biol Reprod, 2012, 87(2):44

PubMed: 22592496 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )
PLoS One, 2012, 7(4):e34684

PubMed: 22514654 ( click the link to review the publication )

Exp Mol Pathol, 2012, 93(1):99-110

PubMed: 22475623 ( click the link to review the publication )

Steroids, 2012, 77(11):1025-32

PubMed: 22683670 ( click the link to review the publication )

J Biomol Screen, 2012, 17(9):1231-42

PubMed: 22927676 ( click the link to review the publication )

J Biomol Screen, 2012, 17(5):572-80

PubMed: 22357874 ( click the link to review the publication )

Biochem Cell Biol, 2012, 90(2):224-31

PubMed: 22397456 ( click the link to review the publication )

Saint Louis University, 2012, 2012/0270829

PubMed: ( click the link to review the publication )

Sarcoma, 2012, 2012:805614

PubMed: 22919280 ( click the link to review the publication )

Blood, 2011, 118(14):3922-31

PubMed: 21841164 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Development, 2011, 138(14):2903-8

PubMed: 21653611 ( click the link to review the publication )

Br J Haematol, 2011, 155(5):588-98

PubMed: 21950728 ( click the link to review the publication )

J Virol, 2011, 85(6):2781-92

PubMed: 21228236 ( click the link to review the publication )

J Biol Chem, 2011, 286(18):16018-29

PubMed: 21454483 ( click the link to review the publication )

Exp Cell Res, 2011, 317(18):2671-82

PubMed: 21871886 ( click the link to review the publication )

Int Immunopharmacol, 2011, 11(12):2242-5

PubMed: 21979495 ( click the link to review the publication )

PLoS ONE, 2011,

PubMed: 21949687 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23712

PubMed: 21887304 ( click the link to review the publication )

Cell Biochem Biophys, 2011, 60(3):173-85

PubMed: 21132543 ( click the link to review the publication )

University of Porto, 2011, Mireia Vila Gasull

PubMed: ( click the link to review the publication )

Glia, 2010, 58(16):1961-76

PubMed: 20830808 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

J Virol, 2010, 84(18):9439-51

PubMed: 20592098 ( click the link to review the publication )

J Biol Chem, 2010, 285(52):41074-86

PubMed: 20956535 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

Targets

NF-κB ^[6] ()	20S proteasome ^[1] (Cell-free assay)
	0.6 nM(Ki)

In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1838	M2PFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnS[41rUUN3ME20NVg3NjN{IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
IMR-5	M1zmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XXRWlEPTB;M{SwPU43OiEQvF2=	NH3oVWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TE-441-T	NUG3Umc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ3MkGuO{DPxE1?	M1LRO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
U-698-M	NEWxbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;z[WxKSzVyPUKyOlIvOTVizszN	MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COLO-824	MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF{NkGuO\|gh\|ryP	Mor2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
P31-FUJ	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFzMUKuO\|Uh\|ryP	NXfq[YVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KY821	NVnYXY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWL4dlNKUUN3ME2xNFM3NjB2IN88US=>	NUHwN3g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RPMI-8866	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFyME[uNlgh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TC-YIK	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXLfnNKSzVyPUe4NU4xOSCwTR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MS-1	M{X0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnKUmtKSzVyPUe1PU41OiCwTR?=	NInzT2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DMS-153	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\WZplPUUN3ME23OFYvQDNibl2=	MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SUP-T1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTZ6Nj6wOEBvVQ>?	M1jXVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SCC-15	M4\2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVznXI4{UUN3ME22OlcvPDdibl2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MSTO-211H	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITNeGhKSzVyPUW3OE4zPiCwTR?=	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	M4j5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHoTWM2OD13M{KuOVchdk1?	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H889	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTR4MT65NkBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CPC-N	M3fmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTYc4tJUUN3ME20NFMvPzdibl2=	NIrnVmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
COLO-668	NHfacWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDjTWM2OD12MEOuOVchdk1?	M3riWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H226	NV7GWXU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\GWVdKSzVyPUSwN{4zOyCwTR?=	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TUR	MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M32wb2lEPTB;M{m2MlYyKG6P	NFjrXGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DEL	NVS2RWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPJbYpKSzVyPUO5NU4zPyCwTR?=	NYLE[VlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1963	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDlTWM2OD1\|OE[uNVkhdk1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CA46	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfNSXNiUUN3ME2zO\|MvPjNibl2=	MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SNU-C1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTN4Mj6wPUBvVQ>?	MlTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
THP-1	NHLEblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG2TWM2OD1\|MkKuOkBvVQ>?	M3PpS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SCH	M{K3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTN{Mj6yNkBvVQ>?	M{[2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1522	NETUOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4GyVWlEPTB;M{C3MlA2KG6P	M3TzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LNCaP-Clone-FGC	NETWfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHf4dWVKSzVyPUK5OU4zPiCwTR?=	M3;pSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H2171	NUfJVZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\zTWM2OD1{OEiuPVIhdk1?	NV;LdIN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H187	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjEPJZJUUN3ME2yPFcvODhibl2=	NH\tcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KASUMI-1	NFKzTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJ6Mz6wOUBvVQ>?	MoDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SK-MEL-2	M1;iO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Tw[WlEPTB;MkixMlkhdk1?	NHKzd4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EW-22	M4n5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfmR\|BKSzVyPUK2N{44PSCwTR?=	M2XBb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1299	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJ4MT63NUBvVQ>?	MorqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COR-L279	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorTTWM2OD1{NUKuNVchdk1?	NUPXWpZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1155	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jqeWlEPTB;MkOwMlMzKG6P	NYLQfmpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1395	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJzMD6xN{BvVQ>?	M3zTN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KM-H2	M2r2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;NNWNKSzVyPUG5O{4xPSCwTR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H209	NFj3XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVu5ZZJZUUN3ME2xPVYvPTJibl2=	M3zKUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H510A	NXvrT4d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfROmN[UUN3ME2xPFUvOzdibl2=	NV[0WGFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1304	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2CxfGlEPTB;MU[5MlIyKG6P	NIrjeoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SCLC-21H	NV;3VGRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3iw[2lEPTB;MUW5MlQyKG6P	MorVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H524	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\qWZkzUUN3ME2xOVkvOSCwTR?=	M2PWfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MC116	NYDkOJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTF2OD64OUBvVQ>?	M3HueVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
BV-173	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\HTWM2OD1zMkKuO\|Ehdk1?	NF\QO2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MHH-CALL-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Pr[GlEPTB;MUG1Mlchdk1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1650	NF\BR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTQTWM2OD1zMUWuNlkhdk1?	M4PHPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ST486	M4P2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHOwfINKSzVyPUGxOE4xPiCwTR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
GR-ST	NEPGRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFzMz6zOEBvVQ>?	NWf6NFlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SIG-M5	MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTFyNT6wOkBvVQ>?	NUS3VHRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1770	M3XGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTFyMj60PUBvVQ>?	MlfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RH-1	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjU[FNKSzVyPUm5Mlg2KG6P	M1L2e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
AM-38	NX\5WI5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlL0TWM2OD16OD6wPEBvVQ>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RL	NHjPemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXjTWM2OD16Nj6wPUBvVQ>?	Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CAL-148	NGfqR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjaTWM2OD16MT64OEBvVQ>?	M2\vVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SK-N-FI	NGX6d\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvMWFdKSzVyPUiwMlIhdk1?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-11	NY\vbIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTd6LkWyJI5O	Mlz2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EW-13	M3;CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml32TWM2OD15Nz63OkBvVQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ALL-PO	NFvS[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfvTWM2OD15Nz62OkBvVQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KP-N-YS	NIXmfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTqVllKSzVyPUe2Mlc1KG6P	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KMS-12-PE	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfQW5dKSzVyPUe2MlI1KG6P	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H128	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmP0TWM2OD15ND63O{BvVQ>?	M4m0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H322M	NV;jWlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{OyNWlEPTB;Nk[uNVEhdk1?	NFHJcXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BT-474	M13qeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofHTWM2OD14NTDuUS=>	M3vJN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MRK-nu-1	NYHjNXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTZzLkiyJI5O	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
YT	M1vYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTZzLkigcm0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LP-1	NFX6ZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlu5TWM2OD14MT6yPEBvVQ>?	NIrDPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
P30-OHK	NIS4b49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HkeWlEPTB;NUSuOlEhdk1?	M3vSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-N87	NXjjZ5JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTV2LkG4JI5O	NF74V\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TALL-1	NF7NVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoKzTWM2OD13Mz65NUBvVQ>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MC-CAR	NFvUOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCwTWM2OD13MT61NkBvVQ>?	NGHiN5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H720	M2juOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDqVYZKSzVyPUWxMlEyKG6P	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RS4-11	NFzQV\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXwUmxKSzVyPUWwMlg5KG6P	NX21dVZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
DMS-79	MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rDSGlEPTB;NUCuO\|Ehdk1?	NITvflk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H716	NFn2PIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInWUoNKSzVyPUS4MlgyKG6P	NVzMOmtsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RPMI-6666	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTKZlgzUUN3ME20OU45QSCwTR?=	NHi3XWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
L-428	NF7oZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i0e2lEPTB;NEOuPFYhdk1?	M4PuSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SKM-1	NH60N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrKTWM2OD12Mj62N{BvVQ>?	M37PVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H2227	NF6yRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3WyXGlEPTB;NECuOFkhdk1?	NWnrbmtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SHP-77	NGHKenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLyelZKSzVyPUO4MlA{KG6P	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
D-283MED	M1;rT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfocXFKSzVyPUO3Mlc6KG6P	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MDA-MB-134-VI	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2KzOGlEPTB;M{WuPFchdk1?	MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
C8166	M2\JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TJOGlEPTB;M{WuO{BvVQ>?	NYnHUmh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
UACC-812	NXzQT\|JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXHTWM2OD1\|NT60OEBvVQ>?	NFjhe5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ES3	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvGT2lKSzVyPUO1MlE6KG6P	NVTSNVVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SK-MEL-1	NGDxTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnLRVhKSzVyPUO1MlE4KG6P	NFP1[pg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KARPAS-422	M{nWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[xW5VKSzVyPUO1MlA1KG6P	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H719	M3;3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLmU2JKSzVyPUO0MlMyKG6P	NFLIOHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H526	NWXDTnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjITWxKSzVyPUOyMlU1KG6P	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EW-3	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\n[mFiUUN3ME2zNE42QSCwTR?=	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
OCI-AML2	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLBTWM2OD1{OT62PUBvVQ>?	Ml61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ECC4	NYO1O4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjUc3E5UUN3ME2yPE44QSCwTR?=	NFnY[YU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
WSU-NHL	NUTSTYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYX2[5dLUUN3ME2yPE4{QSCwTR?=	NUjtXJZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NH-12	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTJ5Lk[3JI5O	M{TDblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LU-165	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJ4LkeyJI5O	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
REH	NYXSfoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvBTWM2OD1{Nj60NUBvVQ>?	NF\2[WU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LS-1034	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XvcWlEPTB;MkWuO\|Uhdk1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HDLM-2	M1zGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTQWXlKSzVyPUK0MlU1KG6P	Mn7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EC-GI-10	NG\mOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1T0W2lEPTB;MkSuNlMhdk1?	NXvJd4VtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
IM-9	NIC3T\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nP[2lEPTB;MkOuOVQhdk1?	NGHDTG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DOHH-2	NHHiW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TiZWlEPTB;MkOuOFUhdk1?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SIMA	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXleYVxUUN3ME2yN{4{QCCwTR?=	M1zab\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EW-12	M1;XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLuOlNKSzVyPUKzMlE4KG6P	NEOyS3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HCC2157	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;mOmlEPTB;MkOuNVMhdk1?	NV:xXYxSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H82	MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vUfGlEPTB;MkOuNFIhdk1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
IST-MES1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXSOJdSUUN3ME2yNk44PyCwTR?=	NYjIdVV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H446	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M170c2lEPTB;MkGuNVghdk1?	M1u5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SF539	NXPxV5JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn2doFFUUN3ME2yNE43PyCwTR?=	MoHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TE-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJyLkC4JI5O	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HCC2218	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrKXlF5UUN3ME2xPU42KG6P	M3jTOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DG-75	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr4eXlKSzVyPUG4MlYyKG6P	NEXBU489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCCIT	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTF6LkO2JI5O	NW\PV45FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EoL-1-	NE\nblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4f1fGlEPTB;MUiuN\|Ehdk1?	Ml7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EB2	M1PqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfoTnlKSzVyPUG4MlA5KG6P	NXLrbGpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB14	M4nOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7BTWM2OD1zNz65PEBvVQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-18	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTF5Lkm2JI5O	Ml;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MFM-223	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\KOHI{UUN3ME2xO{46OSCwTR?=	NIfzfGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
COLO-800	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLFXFBKSzVyPUG3MlY1KG6P	M2qxcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
GOTO	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfo[XRKSzVyPUG3MlA3KG6P	NFj6NHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1436	M4nzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\qeGlEPTB;MUeuNFEhdk1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
U-87-MG	M2Tve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTF4Lke2JI5O	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TGW	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zkVmlEPTB;MU[uOFghdk1?	Mlm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
JAR	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrTTWM2OD1zNj6xN{BvVQ>?	Mki5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB7	MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF3LkmyJI5O	NILNU4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-SNU-1	M4jCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrpTWM2OD1zMz6xPUBvVQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
JVM-3	M4TzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH0b4ZKSzVyPUGyMlk6KG6P	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1581	NYHReGpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\4TWM2OD1zMj6yPEBvVQ>?	NV\QWYFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H23	NVS1O5FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFO4PIdKSzVyPUGyMlEzKG6P	Ml34QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HCC1599	M1rwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TvfmlEPTB;MUGuPVEhdk1?	M4rJNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ES5	NWDDbYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFyLkO4JI5O	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H2081	NUPlV40zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrvVHpDUUN3ME2xNE4xQSCwTR?=	M2DuRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
CTB-1	M4DIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXqT21KSzVyPUmuOlchdk1?	M3fPT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DMS-114	NYPmPIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D2[2lEPTB;OT62NkBvVQ>?	NF3Dc2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SK-NEP-1	NGrQSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrUTWM2OD17LkCxJI5O	NWHQTmVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ATN-1	M1Hhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWC4OZdMUUN3ME24Mlg6KG6P	NVzRfpVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MLMA	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXCTWM2OD16Lki1JI5O	M1mwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NB6	NXfWPJczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPqTWM2OD16LkS4JI5O	M2Dk[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MN-60	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LF[GlEPTB;OD6xOEBvVQ>?	NHvMfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KG-1	MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\qUnVyUUN3ME23Mlk1KG6P	Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
L-363	M2S3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTdwNzDuUS=>	M4nXWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-SNU-16	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTdwNkWgcm0>	NGHzXoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1694	Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTdwNUigcm0>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LU-134-A	M2DCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDFU4hCUUN3ME23MlM6KG6P	M4LzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
JVM-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i3dWlEPTB;Nz6yPEBvVQ>?	M1mydFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SU-DHL-1	NUfUZ4trT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PKWmlEPTB;Nz6yOEBvVQ>?	NGntU\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H345	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYT3eWVHUUN3ME23MlIhdk1?	MlnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB1	NEPYTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTZwOEigcm0>	NX;3d5JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H2196	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PM[GlEPTB;Nj64JI5O	MnTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
GDM-1	M{nwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfCd2VKSzVyPU[uO\|chdk1?	NHXGT4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BC-3	M{KweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTZwNkGgcm0>	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
D-502MG	NYXkN2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTzT45KSzVyPU[uN\|chdk1?	NWGyUnRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LU-65	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1WwbmlEPTB;NT64OEBvVQ>?	NHvTRlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1417	NELsOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2KxbWlEPTB;NT61NUBvVQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-1	M33vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHMSopKSzVyPUWuN\|Ehdk1?	NVX4bXNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SW962	NH3FTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjRTWM2OD13LkKxJI5O	MkO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-SNU-5	NEDjZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXROXNKSzVyPUWuNVchdk1?	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LU-139	M3PUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe3[WNKSzVyPUWuNVMhdk1?	Mk\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CHP-126	M{PBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojDTWM2OD13LkC2JI5O	NFXYXFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SBC-1	NGrxcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHiTWM2OD13LkCxJI5O	NVnrUVhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003	M2jqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDWbpJKSzVyPUWgcm0>	NW\K[Xl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MHH-NB-11	NF3x[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHXVVY5UUN3ME20MlkyKG6P	M{LmeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	M3;5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml35TWM2OD12Lki2JI5O	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
IST-SL1	NFXJWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTRwNkigcm0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HL-60	M{nTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLrVnlEUUN3ME20MlY4KG6P	MlXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NALM-6	M4rlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXpTWM2OD12LkS5JI5O	M3HoNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
Raji	NIKyT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDRTWM2OD12LkS2JI5O	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NOMO-1	M1GxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTQZ4RPUUN3ME20MlM{KG6P	M3y3XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TE-12	M{\LPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTRwMkWgcm0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LB647-SCLC	M16yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTRwMkKgcm0>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
OMC-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTRwMUigcm0>	NFvPVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1648	M{HDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTRwMUOgcm0>	MlPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
K-562	M2LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\rTWM2OD12LkGyJI5O	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H2141	NUK2bVVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XBdGlEPTB;ND6wOUBvVQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HD-MY-Z	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DzfGlEPTB;Mz65N{BvVQ>?	NGTzdnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
RCC10RGB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zKV2lEPTB;Mz65N{BvVQ>?	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COLO-320-HSR	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTNwOUKgcm0>	MmiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RL95-2	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTNwN{mgcm0>	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LC-1F	NWLac2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEm1emRKSzVyPUOuO\|Qhdk1?	M3uwb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NMC-G1	MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NET1WFBKSzVyPUOuOlghdk1?	NWLRR3Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
COLO-684	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjnTWM2OD1\|Lk[2JI5O	MkfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
DJM-1	M{L2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTzWJRKSzVyPUOuOlMhdk1?	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EVSA-T	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILHdmFKSzVyPUOuOkBvVQ>?	NWjC[IRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
no-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPRcXZ2UUN3ME2zMlU2KG6P	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MZ1-PC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\nfpVKSzVyPUOuOVQhdk1?	NUPpOY94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HCC1187	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HoU2lEPTB;Mz61OEBvVQ>?	NH7LZo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KARPAS-45	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTNwNUSgcm0>	NGDTSYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
RPMI-8402	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjCNmZKSzVyPUOuOUBvVQ>?	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LOXIMVI	NXiwT2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Xte2lEPTB;Mz61JI5O	NYK1N21YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MEG-01	NEPRSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTNwNEmgcm0>	Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LAMA-84	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HDZmlEPTB;Mz60PUBvVQ>?	NYLCdHI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
COR-L88	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTxRXVDUUN3ME2zMlQ4KG6P	NY\hSoV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-15	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDYem9KSzVyPUOuOFMhdk1?	Mm\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
DB	NGT2RmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7OTWM2OD1\|LkSxJI5O	NH\ncnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB996-RCC	NYTEU2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTNwNDDuUS=>	NWPSXY9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NEC8	NHvZVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PzU2lEPTB;Mz6zOUBvVQ>?	NEfhS4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SK-N-DZ	M13XTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnX3TWM2OD1\|LkK2JI5O	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CW-2	NX;hO4pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTNwMkGgcm0>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnezTWM2OD1\|LkG0JI5O	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CGTH-W-1	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDTTWM2OD1\|LkGgcm0>	M3PsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MONO-MAC-6	M4fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfCTWM2OD1\|LkGgcm0>	NIjhOIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KARPAS-299	NF3PNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHv1eFNKSzVyPUOuNFYhdk1?	MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HT	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3SfZFKSzVyPUOuNFIhdk1?	NWLmOXBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SW954	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIe1ZnZKSzVyPUKuPUBvVQ>?	M1m4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MOLT-16	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;HSGlEPTB;Mj64PUBvVQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
C2BBe1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LKPGlEPTB;Mj64PUBvVQ>?	NEjseIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ETK-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3KbGJJUUN3ME2yMlg1KG6P	NHjLeFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CTV-1	NVKyb3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnY[\|VGUUN3ME2yMlghdk1?	NYLJfJJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EW-16	NEjxOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHpOmxsUUN3ME2yMlc2KG6P	MknMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
Mo-T	NYDDcJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn36TWM2OD1{Lke0JI5O	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EB-3	NWDke5BXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJwNk[gcm0>	NGP4VJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB1047-RCC	M{W5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LSO2lEPTB;Mj61O{BvVQ>?	M3Pie\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KNS-81-FD	NFvFN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTo[29KSzVyPUKuOFghdk1?	NV7ETnNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB69	M1L6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljRTWM2OD1{LkS2JI5O	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H64	NWriZYxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3voZmlEPTB;Mj60OEBvVQ>?	M3XmR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KU812	NWfOUXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17mUmlEPTB;Mj60NkBvVQ>?	MmDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H748	NHP0UmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTJwM{mgcm0>	NYj2dHd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ARH-77	MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTJwM{igcm0>	MlTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SCC-3	NVTRUVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXxTWM2OD1{LkO3JI5O	Mk[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RPMI-8226	NV73T2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\uUWlEPTB;Mj6zOUBvVQ>?	NUHiW5lxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB10	M3qzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzWUYQ5UUN3ME2yMlMzKG6P	M4qxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
BC-1	NXrOSFRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fhSWlEPTB;Mj6zNUBvVQ>?	NUTBWGRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB5	NEDtTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETRVoNKSzVyPUKuNlchdk1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KMOE-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTsTWM2OD1{LkKzJI5O	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SJSA-1	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrj[Y9KSzVyPUKuNlEhdk1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ES4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HhO2lEPTB;Mj6xOkBvVQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KGN	NX;2fnNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYraWIZEUUN3ME2yMlE2KG6P	NGXyRY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EKVX	M3LSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\n[XlKSzVyPUKuNVQhdk1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MOLT-4	M1;ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13oWGlEPTB;Mj6xN{BvVQ>?	MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KE-37	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzlS5NKSzVyPUKuNVMhdk1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HH	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v6RmlEPTB;Mj6xN{BvVQ>?	NYPzbWJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
GT3TKB	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7ZfpRKSzVyPUKuNVIhdk1?	NX;hOIFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BL-70	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi4VGRKSzVyPUKuNVIhdk1?	MlrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NOS-1	M1TZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\CT\|k4UUN3ME2yMlEyKG6P	NInaWoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EW-24	NWLrTFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;jdY5wUUN3ME2yMlA5KG6P	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LAN-6	NYrFUJpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJwMEWgcm0>	M2KwU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NB17	NIXkU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3BO2NoUUN3ME2yMlA1KG6P	NHLLWVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LS-123	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnXTWM2OD1{LkCyJI5O	NYTPcYRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB13	NGnsbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJibl2=	NH3MSpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NKM-1	NHjESIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTJibl2=	M1HYXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
697	NGfnSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnUbVJKSzVyPUGuPVkhdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
BE-13	M{K4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjneI9KSzVyPUGuPVMhdk1?	NUHKXlJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MPP-89	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwOEmgcm0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
Becker	NETCUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL1VWNKSzVyPUGuPFMhdk1?	NH3t[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MV-4-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXXTWM2OD1zLkiyJI5O	MkHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
GB-1	NYHq[\|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PXXWlEPTB;MT64NUBvVQ>?	MoGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1092	NHi4SI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TlemlEPTB;MT64JI5O	MnXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2126	NFTROnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4j6V2lEPTB;MT64JI5O	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LC4-1	M4PDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTFwN{mgcm0>	NV:1VFdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
U-266	NEi2Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWKzfJltUUN3ME2xMlc3KG6P	MlTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KURAMOCHI	NU[z[YZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHLTWM2OD1zLkeyJI5O	M{SwV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TGBC1TKB	M2ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\FTWM2OD1zLkexJI5O	M3HJW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EHEB	NIjPNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFqwZlFKSzVyPUGuOlchdk1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
GCIY	M2i5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvFTWM2OD1zLk[yJI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HEL	NHO5OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L4OGlEPTB;MT62NUBvVQ>?	MnzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB12	NF\ueo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTFwNU[gcm0>	NWTSdHZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H69	NWDNTnFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDjTWM2OD1zLkW0JI5O	MnfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LS-411N	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPQTWM2OD1zLkWzJI5O	NHfhdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
PF-382	M1\HW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Dab2lEPTB;MT60O{BvVQ>?	MlHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CAS-1	NIrXcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFwM{egcm0>	NG[yTZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
L-540	M4L2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnv5TWM2OD1zLkO3JI5O	M4WySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ECC12	NHG5T4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTsZYJ6UUN3ME2xMlM4KG6P	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
DU-4475	NUnsWGw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPvPFVKSzVyPUGuN\|Yhdk1?	M3vlVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
OPM-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTFwM{Ogcm0>	NFm1PHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
IST-SL2	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHT5bmFKSzVyPUGuN\|Ehdk1?	MlzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
Calu-6	M2XKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHYPHZVUUN3ME2xMlI6KG6P	M2X4XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
CMK	M2K3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTFwMkmgcm0>	NXfrbJFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
A3-KAW	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn6To94UUN3ME2xMlI5KG6P	M13uPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
K5	NYjLZ4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln5TWM2OD1zLkK4JI5O	NUnOSIp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KM12	NWK3c\|h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\pWWNKSzVyPUGuNlchdk1?	NU\BTWx{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SR	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTFwMkWgcm0>	NInTflU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BL-41	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFwMkWgcm0>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
Daudi	NHfnWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzzXm44UUN3ME2xMlIzKG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1882	M33PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rnNmlEPTB;MT6yJI5O	MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TE-8	M4nEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlryTWM2OD1zLkG5JI5O	NHHseZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HAL-01	M2ro[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHXTWM2OD1zLkG4JI5O	Mn;4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EM-2	M1H6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fMWGlEPTB;MT6xOkBvVQ>?	NUTT[25kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
CCRF-CEM	NIHQdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnKyTWM2OD1zLkGzJI5O	NESyUnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
D-392MG	NWriXpJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfHOFdKSzVyPUGuNUBvVQ>?	MlzyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MZ7-mel	M3vxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFwMEmgcm0>	MnrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
VA-ES-BJ	M3H4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofRTWM2OD1zLkC5JI5O	MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SK-MM-2	NYfJVmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLsTWM2OD1zLkC5JI5O	MlvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LC-2-ad	NG\mclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zwS2lEPTB;MT6wPEBvVQ>?	M{LBXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
RKO	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1K5R2lEPTB;MT6wOkBvVQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TE-10	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7KTWM2OD1zLkCzJI5O	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TE-1	NVruWJliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfQZ2JKSzVyPUGuNFMhdk1?	NIfLR4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
PSN1	M3vaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLOTWM2OD1zLkCxJI5O	M1f3Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SW872	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfSZ\|NKSzVyPUCuPVk3KG6P	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HC-1	NW\FV2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHiy[JZKSzVyPUCuPVc2KG6P	MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KALS-1	M3zTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHO3S2lKSzVyPUCuPVI2KG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SF268	NFL0V5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULsfnZNUUN3ME2wMlkzOyCwTR?=	M3jNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
IST-MEL1	NX3JVVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\4e3JKSzVyPUCuPVE4KG6P	NU\3WGFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RXF393	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTkTWM2OD1yLkmxOEBvVQ>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SNB75	M3q2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3n0e2lEPTB;MD65NVIhdk1?	NYDSSWFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1355	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHCcpN7UUN3ME2wMlg6PSCwTR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TE-5	M1L1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7RNYlKSzVyPUCuPFY2KG6P	NG\IUWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
QIMR-WIL	NIrt[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTBwOEi5JI5O	M4DqUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SK-LMS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr0T4tKSzVyPUCuPFU1KG6P	MlrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SW684	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLPcHhzUUN3ME2wMlgzOSCwTR?=	M1j6SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ML-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwOEKxJI5O	NYewRpZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-263MG	M3i4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4W3WGlEPTB;MD64NFchdk1?	NFX0VHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB2241-RCC	NGO4dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7tXHpVUUN3ME2wMlgxPCCwTR?=	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
GI-1	M3LkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTBwN{[0JI5O	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ES7	M3;3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS1TWM2OD1yLke2OkBvVQ>?	NHe4SJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LS-513	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;xTWM2OD1yLkezPUBvVQ>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KINGS-1	M3[0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\kTWM2OD1yLkeyNkBvVQ>?	M3LJeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
UACC-257	NEDMR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXaTIlKSzVyPUCuO\|Ehdk1?	MlO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LB373-MEL-D	NX;O[m9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDoXYRKSzVyPUCuO{BvVQ>?	MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SF126	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3ITYoyUUN3ME2wMlcxOSCwTR?=	NWrufI5{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	NXXMfoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwNkmzJI5O	NUXWT3cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TK10	NUL2dY81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\nU5lPUUN3ME2wMlY4QSCwTR?=	M3fLUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
D-336MG	NVfvXFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zWd2lEPTB;MD62OVchdk1?	NXXWfZpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BB49-HNC	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofuTWM2OD1yLk[1NkBvVQ>?	M2P0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HOP-62	NHTpNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\RTWM2OD1yLk[0O{BvVQ>?	NVHxN4ppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LB831-BLC	M2PVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPhWpJIUUN3ME2wMlY1OSCwTR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
GI-ME-N	M2O3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTBwNkO0JI5O	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
A4-Fuk	NHX5fXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\4Z25LUUN3ME2wMlYzOyCwTR?=	NFrLTok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HT-144	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\kTWM2OD1yLkW3OkBvVQ>?	NEG5So49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
COLO-829	NHTNWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwNkG0JI5O	NIHyS5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H747	NFLuNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwNUO5JI5O	MmO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CESS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDvZlNnUUN3ME2wMlU{QCCwTR?=	NXfCeZFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HUTU-80	M2SxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknqTWM2OD1yLkWzN{BvVQ>?	NUHH[plMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
DSH1	MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\QTWM2OD1yLkS4JI5O	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LB771-HNC	NXLJZ\|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjmPY13UUN3ME2wMlQ4PCCwTR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CP66-MEL	M2Poe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwNEezJI5O	NGqzW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
OCUB-M	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33sVmlEPTB;MD60OFchdk1?	M3X1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MFH-ino	NWjXdYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\aSnRLUUN3ME2wMlQ1OyCwTR?=	M3O3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
OS-RC-2	NVj1TZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETHWlNKSzVyPUCuOFQhdk1?	MnvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HCE-T	M1qx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HrdWlEPTB;MD60N\|khdk1?	NVzCOXg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ES1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTBwNEOgcm0>	NWTnVoo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	M{Hpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPTTnJKSzVyPUCuOFI2KG6P	NWXWUo11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ACN	MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIn6d4RKSzVyPUCuOFE4KG6P	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
D-247MG	NHzSUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33Bb2lEPTB;MD60NVMhdk1?	NVPjd2NPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HCC2998	NXvWfJh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW3elhKSzVyPUCuOFEzKG6P	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MZ2-MEL	M1vDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTZc2FKSzVyPUCuOFA4KG6P	M{\LUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ES8	NVHWXnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjBU5FvUUN3ME2wMlQhdk1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
A388	NW\ne2d1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTBwM{W2JI5O	NYT4eINjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KS-1	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrYTWM2OD1yLkO0JI5O	Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
BB30-HNC	M{juXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4K5cmlEPTB;MD6zN\|Uhdk1?	M3jsbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ONS-76	NUK1bGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTBwM{Ogcm0>	M2fVUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
D-542MG	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XyNWlEPTB;MD6zNlkhdk1?	NEDZfnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BB65-RCC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwM{C0JI5O	NEnuO3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LOUCY	M1vDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwMkmzJI5O	NFjF[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
OVCAR-4	M{jHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL5TWM2OD1yLkK4PUBvVQ>?	NW\kPXVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LXF-289	M3XmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXFTWM2OD1yLkK2PUBvVQ>?	NVfNPId3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KNS-42	NXf6VpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3jTWM2OD1yLkK1PEBvVQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
8-MG-BA	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDEeHp[UUN3ME2wMlI2KG6P	NHjiSno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	NFPRb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnXN3c1UUN3ME2wMlI1OyCwTR?=	NFv0Wo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
A101D	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDZdoFKSzVyPUCuNlI2KG6P	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MMAC-SF	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPme41kUUN3ME2wMlIyPiCwTR?=	NIiyeHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
no-10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwMkGgcm0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
A253	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHO1U\|ZKSzVyPUCuNlA5KG6P	MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TE-9	M2HrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjDVWdKSzVyPUCuNVgzKG6P	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SH-4	M{j5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMUezJI5O	M17zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SK-UT-1	NWPWdFBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjUTWM2OD1yLkG2N{BvVQ>?	MofYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ES6	NWjTVVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWew[lJxUUN3ME2wMlAxOjFibl2=	NIjXOIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
human PBMC	MnXrSpVv[3Srb36gRZN{[Xl?	MnXWNVAxKG6P	MlS5NlQhcA>?		NGKze2ZKdmS3Y3XzJGlNNThicnXs[YF{\Q>?	NVrRdVdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVE1PzdpPkK1O\|kyPDd5PD;hQi=>
U937	NE\IPWZHfW6ldHnvckBCe3OjeR?=	MXGxNFAhdk1?	NYDsbmhGPiCq		MVHJcoR2[2W\|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{	NGrMWZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NVQ4Pyd-MkW3PVE1Pzd:L3G+
HH	MVzNbYdz[XSrb36gRZN{[Xl?	NF;S[2cyODBibl2=	NVjlRY5jOjRiaB?=	NGGzSVZFVVOR	MlzSVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?=	NELPWnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NVM{PSd-MkW2PFE{OzV:L3G+
Hut-78	MYHNbYdz[XSrb36gRZN{[Xl?	NUnzO4JOOTByIH7N	NF[wUZUzPCCq	NV3oV3E6TE2VTx?=	M4\yOHJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
HH	M3SyUWZ2dmO2aX;uJGF{e2G7	Ml\HNVAxKG6P	NH6xZ5gzPCCq	NYj5XXRHTE2VTx?=	M{\pTIRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
H9	M4r5[mZ2dmO2aX;uJGF{e2G7	NVrMPIRnOTByIH7N	MlzHNlQhcA>?	NFLqWXFFVVOR	NVfVcZFXTG:5boLl[5Vt[XSnczDUS2Yu\|rJzIHHu[EBKVC1zMTDlfJBz\XO\|aX;u	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
Hut-78	M4m2XGZ2dmO2aX;uJGF{e2G7	M{DhSlExOCCwTR?=	NFvBV4YzPCCq	NH\vVVhFVVOR	MYLEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25?	MkHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OEGzN\|UoRjJ3NkixN\|M2RC:jPh?=
H1299	MULBdI9xfG:\|aYOgRZN{[Xl?	NUjMW3ZGQDBibl2=	NHz2S4YzPCCq	NVHpdldLTE2VTx?=	NHHJWY1U\W6\|aYTpfoV{KE6VQ1zDJINmdGy\|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?=	MkjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MkO2PVMoRjJ3M{KzOlk{RC:jPh?=
BLM	MX;BeZRweGijZ4mgRZN{[Xl?	MYqxNEBvVQ>?	NHXuT\|YyOiCq		NF;xdFJKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:\|b33ldy=>	NFnyVo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3PVA5Oyd-MkOwO\|kxQDN:L3G+
A375	M1HPSWF2fG:yaHHnfUBCe3OjeR?=	NGW3UnMyOCCwTR?=	NYTCZnEzOTJiaB?=		NF3rXHBKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:\|b33ldy=>	NGOzSWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3PVA5Oyd-MkOwO\|kxQDN:L3G+
BLM	M3XCWmFxd3C2b4Ppd{BCe3OjeR?=	NET4boYyOCCwTR?=	NFvoS2gzPCCq		M2iwbWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{mwPFMoRjJ\|MEe5NFg{RC:jPh?=
A375	NH\YW\|NCeG:ydH;zbZMhSXO\|YYm=	MUWxNEBvVQ>?	MYeyOEBp		MVfJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MoPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{mwPFMoRjJ\|MEe5NFg{RC:jPh?=
RAW 264.7	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHZNVAxKG6P	MkDuOFghcA>?		M4LKSnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NF34XWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSyO\|E2PCd-MkK0NlcyPTR:L3G+
SNK-6	NHPld29CdnSrdnnyZYwhSXO\|YYm=	MWOxJO69VQ>?	NUTBfZRPOjRiaB?=		NXLVcml{UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY	NFTIbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
KAI-3	MmnORY51cX[rcnHsJGF{e2G7	Mof2NUDPxE1?	NXfOVlVOOjRiaB?=		MX;JcoR2[2W\|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
SNT-16	NGLtXndCdnSrdnnyZYwhSXO\|YYm=	NWfxc3BoOSEQvF2=	Mo\uNlQhcA>?		M4Lzfmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
SNT-13	NX\5OI5HSW62aY\pdoFtKEG\|c3H5	NYnBZlg1OSEQvF2=	M333SlI1KGh?		NF;TSotKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
KHYG-1	MX\BdI9xfG:\|aYOgRZN{[Xl?	NVLrPWxkOSEQvF2=	MWG2JIg>		M1L0O2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
KAI-3	M2rPVmFxd3C2b4Ppd{BCe3OjeR?=	MmrmNUDPxE1?	NUXQNFVSPiCq		MnLHTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
Jurkat	NGLoZo5CeG:ydH;zbZMhSXO\|YYm=	NXzt[GRsOSEQvF2=	MmGwOkBp		M{DMZWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
SNT-16	NYDmfnNMSXCxcITvd4l{KEG\|c3H5	M2DMfFEh\|ryP	NWnWNZV1PiCq		M1rtbmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
KHYG-1	M1\aN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXraNlRWOSEQvF2=	M3HnbVI1KGh?		M2PyRXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	M3fWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
SNK-6	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmxJO69VQ>?	MlHHNlQhcA>?		MVPS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	NXPmbZNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
KAI-3	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHkNUDPxE1?	NX\hU49DOjRiaB?=		M{S2T3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NEjiSJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
Jurkat	NGK3bFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVixJO69VQ>?	M{\uZ\|I1KGh?		M1q3TXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	NH\He5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
SNT-16	NIXPZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvrNUDPxE1?	NVPET5JLOjRiaB?=		M4e2ZXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
SNT-13	NGn4XWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXKxJO69VQ>?	NEiyVFAzPCCq		NHrP[nNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	M3HZcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
BJAB	NGLNUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M12yNVEh\|ryP	MkjRNlQhcA>?		MnHzVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	NFTiemw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
LCL-2	NX25eXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnyxNUDPxE1?	M2fMdFI1KGh?		MVnS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
LCL-1	M{DmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG4NUDPxE1?	MneyNlQhcA>?		M4TXOnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
Raji	M2DDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXexJO69VQ>?	MVKyOEBp		NVe2bXBmWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	M2fBRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
BaF/3-p210	NWLJbW9DTnWwY4Tpc44hSXO\|YYm=	NHnHRZU3KG6P	NGTzNnUzPCCq		NFPjRY9T\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?=	NUfjdYoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFU3QTJpPkKwN\|A2Pjl{PD;hQi=>
BaF/3-p210	M{XUfWZ2dmO2aX;uJGF{e2G7	NXTNVIpQPiCwTR?=	MnPQOFghcA>?		MYDJcoR2[2W\|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0	M{Hze\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C1OlkzLz5{MEOwOVY6OjxxYU6=
BaF/3	NHfjdlZHfW6ldHnvckBCe3OjeR?=	NU\mc3p{PiCwTR?=	Ml3sOFghcA>?		NGPjenhKdmS3Y3XzJIEh\3KnYYSgS\|Eh[2WubD3jfYNt\SCjcoLld5Q>	NEfGZ409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOVY6Oid-MkCzNFU3QTJ:L3G+
TCC-S	NYnm[Il[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrKR3oxOTByIH7N	NXjVcZhVPDhiaB?=		NXfjR4FUUUN3ME2yMlghdk1?	NFnJcYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOVY6Oid-MkCzNFU3QTJ:L3G+
BaF/3-p210	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfGU4gyODBibl2=	NXG3SIJnPDhiaB?=		MXrJR\|UxRTRwNzDuUS=>	NFfWTGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOVY6Oid-MkCzNFU3QTJ:L3G+
BaF/3	M3zuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TiVFExOCCwTR?=	M1;sUlQ5KGh?		NVTxV5BwUUN3ME22MlIhdk1?	NFTpdpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOVY6Oid-MkCzNFU3QTJ:L3G+
RPMI 8226	NXHKSXdqTnWwY4Tpc44hSXO\|YYm=	M{[2OlIxKG6P	NIW4UW05KGh?		MV3JcoR2[2W\|IFTORUB{gW62aHXzbZM>	M{fP[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEO2NFUxLz5zOUSzOlA2ODxxYU6=
OPM2	Mmj3SpVv[3Srb36gRZN{[Xl?	M4f6c\|IxKG6P	M3TTN\|ghcA>?		NXfzT2s2W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?	NX;DNJF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0N\|YxPTBpPkG5OFM3ODVyPD;hQi=>
INA6	M2Oyd2Z2dmO2aX;uJGF{e2G7	NYj2SHV1OjBibl2=	NIf4[HI5KGh?		NEjJe3lUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	M3vkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEO2NFUxLz5zOUSzOlA2ODxxYU6=
OPM1	NV3oem5nTnWwY4Tpc44hSXO\|YYm=	NF7DWWEzOCCwTR?=	Moj3PEBp		M3TETHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	M{HxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEO2NFUxLz5zOUSzOlA2ODxxYU6=
U266	MVXGeY5kfGmxbjDBd5NigQ>?	MnfSNlAhdk1?	M4fNZVghcA>?		NFXXenFUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	MoLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2M{[wOVAoRjF7NEO2NFUxRC:jPh?=
MM.1S	NE\jZXBHfW6ldHnvckBCe3OjeR?=	MYSyNEBvVQ>?	M2C3VlghcA>?		NILQNVBUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	NFTqW2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSzOlA2OCd-MUm0N\|YxPTB:L3G+
RPMI 8226	NEnW[nJHfW6ldHnvckBCe3OjeR?=	NXKyeXU4OjBibl2=	M{\IRVghcA>?		NHfuS\|dUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	NXzIbplnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0N\|YxPTBpPkG5OFM3ODVyPD;hQi=>
CHLA-255	M1jOT2Z2dmO2aX;uJGF{e2G7	NGjKfpUyOCCwTR?=	MXmyOEBp		M1my[21w\GW\|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn	NXLqPHY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFk3QDRpPkG3Olg6Pjh2PD;hQi=>
NB-1691	M1rlbmZ2dmO2aX;uJGF{e2G7	Mm\INVAhdk1?	MonxNlQhcA>?		NXLhOmdqW2mpbnnmbYNidnSueTDy[YR2[2W\|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>?	NGnGNpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4PVY5PCd-MUe2PFk3QDR:L3G+
SK-N-AS	NXPpT\|c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7lNIkyKM7:TR?=	M3GzT\|czKGh?		MXXJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn	MnjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEm2PFQoRjF5Nki5Olg1RC:jPh?=
CHLA-255	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT6UmQyKM7:TR?=	NHS0O5M4OiCq		NVjkZWdMUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl	MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEm2PFQoRjF5Nki5Olg1RC:jPh?=
NB-1691	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfwV5piOSEQvF2=	M37KWFczKGh?		NGTHR4NKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW=	M1HlZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki5Olg1Lz5zN{[4PVY5PDxxYU6=
HKe-3	MlXRRZBweHSxc3nzJGF{e2G7	NFLhUHM2OCCwTR?=	NV;Sb2VtPDhiaB?=	NXjTUYZOTE2VTx?=	M1;2Wmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	M2fIe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{e4NVc6Lz5zNke3PFE4QTxxYU6=
HCT116	NYnZeJk4SXCxcITvd4l{KEG\|c3H5	Ml;QOVAhdk1?	Moj4OFghcA>?	NInHe3hFVVOR	NIiyTlBKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	Mnn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5N{ixO\|koRjF4N{e4NVc6RC:jPh?=
T29Kt1	MWTBdI9xfG:\|aYOgRZN{[Xl?	NV;0PZdbPTBibl2=	M3PIclQ5KGh?	MY\EUXNQ	M3LhWGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MlSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5N{ixO\|koRjF4N{e4NVc6RC:jPh?=
T29	NIT4XVNCeG:ydH;zbZMhSXO\|YYm=	NVfp[Y5{PTBibl2=	NWXFWGhEPDhiaB?=	MmDjSG1UVw>?	NELEeo9KdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M4LEd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{e4NVc6Lz5zNke3PFE4QTxxYU6=
LNCap-Pro5	NX:wPY93TnWwY4Tpc44hSXO\|YYm=	NHe5VokyKM7:TR?=	NXPsbos6PCCq	NV:zSItsTE2VTx?=	NF;zWHRUfGGkaXzpfoV{KHB3Mx?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDZzMkWzNkc,OTR4MUK1N\|I9N2F-
H460	M3jKT2Z2dmO2aX;uJGF{e2G7	NYTId4dNOTByIH7N	NGnOR4QzPCCq	MVvEUXNQ	MnjHTY5lfWOnczDHNk1ONXCqYYPlJIFzemW\|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>?	M4fobVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkOxOlIxLz5zMk[zNVYzODxxYU6=
H322	NXXDfo9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY[4[pBuOTBizszN	M2ewTlczKGh?	NFHuR4FFVVOR	MojBTWM2OD14MkCgcm0>	NIjtbnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYzOCd-MUK2N\|E3OjB:L3G+
H358	NIWwTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4H1UFExKM7:TR?=	MkfEO\|IhcA>?	M1vHVmROW09?	NEm5TmNKSzVyPUewJI5O	NYCxbFljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OjBpPkGyOlMyPjJyPD;hQi=>
H460	M2rwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjPWFVjOTBizszN	NHHN[4c4OiCq	MV3EUXNQ	M4rW[2lEPTB;MUCwJI5O	M{DpPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkOxOlIxLz5zMk[zNVYzODxxYU6=
RPMI8226/LR5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37zTFUxOCCwZz;tcC=>	NECzVmQ1QCCq	M2fNcWROW09?	NWnxcZJuUW6qaXLpeJMh[2WubDDndo94fGh?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ\|MU[xPUc,OTJ4M{G2NVk9N2F-
U266/dox4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLad4M2ODBibnevcYw>	NIX0OpU1QCCq	NGHpdnJFVVOR	MmrkTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NG\2Vmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYyQSd-MUK2N\|E3OTl:L3G+
U266/LR7	M33tVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\QVpFjPTByIH7nM41t	NITkPWo1QCCq	M3fpTGROW09?	MnPlTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NHTF[XM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYyQSd-MUK2N\|E3OTl:L3G+
WAD-1	NH\qWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rkT\|UxOCCwZz;tcC=>	MYO0PEBp	MmW4SG1UVw>?	NVfvTnF1UW6qaXLpeJMh[2WubDDndo94fGh?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ\|MU[xPUc,OTJ4M{G2NVk9N2F-
ARH77	NXLobZNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWq1NFAhdmdxbXy=	NU\zW5d4PDhiaB?=	NEfFRXNFVVOR	MkPGTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NX\MVVJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OTlpPkGyOlMyPjF7PD;hQi=>
U266	NHzxNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvHOVAxKG6pL33s	NFjXd2Q1QCCq	MXXEUXNQ	M{i2VmlvcGmkaYTzJINmdGxiZ4Lve5Rp	MlPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NVkoRjF{NkOxOlE6RC:jPh?=
H460	MWLGeY5kfGmxbjDBd5NigQ>?	NVTWR2p4OTBizszN	NGjuVXEzPCCq	M2O5XmROW09?	NF\STIJKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2	MmDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2OUKxNVcoRjF{NEmyNVE4RC:jPh?=
UM-SCC-11B	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvqVI56OTByIH7N	M1LoS\|czKGh?	MX\EUXNQ	MnPSTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	NEHxR4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUO1NFkyOyd-MUGzOVA6OTN:L3G+
UM-SCC-9	NIrPWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xNFAhdk1?	M{LUXFczKGh?	NGXKdI1FVVOR	MlvuTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	NHLSXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUO1NFkyOyd-MUGzOVA6OTN:L3G+
B7E3	NHLHNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWmxNFAhdk1?	MoXjO\|IhcA>?	MXHEUXNQ	NUTmVYNiUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	NWXIbXBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
B4B8	M4HRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7PNVJ3OTByIH7N	NFrkUGk4OiCq	NYfzNZYyTE2VTx?=	M{fJUWlvcGmkaYTzJINmdGxidnnhZoltcXS7	NWfLZlN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
PAM-LY2	M4f3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrvc2IyODBibl2=	MVi3NkBp	NH3pdWZFVVOR	M3PkZWlvcGmkaYTzJINmdGxidnnhZoltcXS7	NYHHWYI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
PAM 212	M1L3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTDNVAxKG6P	M2HUSlczKGh?	NVPHZYZ5TE2VTx?=	NInKdldKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NWLmU3RQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
PAM-LY2	M3j2SGZ2dmO2aX;uJGF{e2G7	M{LrRVExOCCwTR?=	MV2xNkBp	NYnzXoNiTE2VTx?=	NIDUWmxKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN3MEmxN{c,OTF\|NUC5NVM9N2F-
Hs Sultan	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\vSWhqOTByIH7N	NEi1cnM1QCCq	M{jKNmROW09?	MVjJR\|UxRTJyIH7N	M1HQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{C2OFg6Lz5zMUOwOlQ5QTxxYU6=
IM-9	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W1UFExOCCwTR?=	M{LRbVQ5KGh?	MVXEUXNQ	MXLJR\|UxRTZibl2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTNyNkS4PUc,OTF\|ME[0PFk9N2F-
U266	NYTk[m9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;oWoMyODBibl2=	MXe0PEBp	NX;EOpN1TE2VTx?=	MmnJTWM2OD1\|IH7N	M{PuNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{C2OFg6Lz5zMUOwOlQ5QTxxYU6=
LR5	NW\qRZFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[3RVExOCCwTR?=	MlL3OFghcA>?	MV\EUXNQ	Ml6yTWM2OD1{MDDuUS=>	MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|ME[0PFkoRjFzM{C2OFg6RC:jPh?=
MR20	NUTVXoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWexNFAhdk1?	NVfL[4pQPDhiaB?=	M{jQemROW09?	NGTtSnZKSzVyPUKwJI5O	NHLHdWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOwOlQ5QSd-MUGzNFY1QDl:L3G+
Dox40	NGrtTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1qyTFExOCCwTR?=	NFXWNFg1QCCq	MUjEUXNQ	MX7JR\|UxRTRyIH7N	NHK3Vm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOwOlQ5QSd-MUGzNFY1QDl:L3G+
RPMI8226	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7xNVAxKG6P	NEX3OYw1QCCq	MWTEUXNQ	NHfwRmZKSzVyPUOwJI5O	NYjPfYVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzNFY1QDlpPkGxN\|A3PDh7PD;hQi=>
OVCA 429	MnzTSpVv[3Srb36gRZN{[Xl?	NHTpRm4{ODBibl2=	Mo\VOFghcA>?	MlWxSG1UVw>?	NETF[5NFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>	NW\CTZZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVk4PjZpPkGwPVk6PzZ4PD;hQi=>
MCF-7	MXTDfZRwfG:6aXOgRZN{[Xl?	NFjIbnQ2OCEQvF2=	NWjDU2x{PDhiaB?=	Mki1SG1UVw>?	MmezT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=>	NXv6c2ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0PVk3PDNpPkGwOFk6PjR\|PD;hQi=>
FSCLL	M3XXRmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHzRVmgzPCCqcoO=		MnPzR2M2OCB;IECuNFA1KM7:TR?=	NIDsdVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[zOFQzQSd-MkG2N\|Q1Ojl:L3G+
HEK293	NGjIVYJEgXSxdH;4bYNqfHliYYPzZZk>		MUGyOEBpenN?		MljDR2M2OCB;IECuN\|Q4KM7:TR?=	M4q3R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFI6Lz5{MU[zOFQzQTxxYU6=
Glioma (HF2303)	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NFjZdWs4OiCqcoO=		M4rTOmVEPTBiPTCwMlAxODdizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6OE[5PUc,OjZ{OEi2PVk9N2F-
Glioma (HF2476)	NEnL[oxEgXSxdH;4bYNqfHliYYPzZZk>		MkP5O\|IhcHK\|		MXrFR\|UxKD1iMD6wNFA4KM7:TR?=	NEjHZos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
Glioma (HF2876)	NXPQbldjS3m2b4TvfIlkcXS7IHHzd4F6		NHriRnk4OiCqcoO=		NGHQSHVGSzVyIE2gNE4xODB5IN88US=>	MljYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
Glioma (HF2885)	NFPUZXVEgXSxdH;4bYNqfHliYYPzZZk>		NHHwS2E4OiCqcoO=		MVjFR\|UxKD1iMD6wNFA4KM7:TR?=	NIH2fm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
Glioma (HF3013)	M2PvZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NXfwbVFDPzJiaILz		MV\FR\|UxKD1iMD6wNFA4KM7:TR?=	NH\hbnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
Glioma (HF2381)	NX;1Z4xtS3m2b4TvfIlkcXS7IHHzd4F6		MoTlO\|IhcHK\|		M{Pxc2VEPTBiPTCwMlAxODdizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6OE[5PUc,OjZ{OEi2PVk9N2F-
Glioma (HF2790)	M4PiW2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M{D1RlczKGi{cx?=		MkHhSWM2OCB;IECuNFAxPyEQvF2=	NF3HZ5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
HepG2	NWLkRnY2S3m2b4TvfIlkcXS7IHHzd4F6		MlPrOFghcHK\|		NXzIcmRUTUN3MDC9JFAvODFizszN	NGixSW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUiwNFgzPyd-Mkm4NFA5Ojd:L3G+
Molt4	NIXTRpRHfW6ldHnvckBie3OjeR?=				NUTJflVZTUN3MDC9JFAvODJzIN88US=>	MlyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OFcoRjF6MkS3OVQ4RC:jPh?=
Molt4	NEDsNHlHfW6ldHnvckBie3OjeR?=				MYTFR\|UxKD1iMD6wNlEh\|ryP	NG\odFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWwN\|M1QSd-MkK1NFM{PDl:L3G+
HL60	NFXK[ZpHfW6ldHnvckBie3OjeR?=		MX[xNEBucW6\|		MoTKSWQ2OCB;IECuNFAzPSEQvF2=	NWfre3NpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NlIzODZpPkG5OFIzOjB4PD;hQi=>
HL60	M4DU[GZ2dmO2aX;uJIF{e2G7		M1HZW\|ExKG2rboO=		NWXVU2FSTUR3MDC9JFAvODB{NTFOwG0>	Mn[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7N{OxNFEoRjJzOUezNVAyRC:jPh?=
RPMI8226	MnHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M4\pNWdKPTBiPTCwMlAxODJ\|IN88US=>	NGXjXZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
CCRF-CEM	NEHUTnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M{PGe2dKPTBiPTCwMlAxODN3IN88US=>	NF;qSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
MDA-MB-435	MmfHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NWq2Z2FDT0l3MDC9JFAvODByNESg{txO	NHjNRpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
MALME-3M	MmfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NHzzboRIUTVyIE2gNE4xODB2NTFOwG0>	M4rPTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
NCI-H226	NFjLeI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MX3HTVUxKD1iMD6wNFA1PiEQvF2=	NXHndopxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SK-MEL-28	M3XyTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NWXsT21oT0l3MDC9JFAvODByNE[g{txO	NHj2Z2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
A498	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NUTBSHBIT0l3MDC9JFAvODByNEig{txO	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
MOLT4	NYLrdmpCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MlfkS2k2OCB;IECuNFAxPTFizszN	NHK5XpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
OVCAR3	NYTz[3hwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NWXKV2llT0l3MDC9JFAvODByNUSg{txO	NXKzXnN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SW620	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M3\3T2dKPTBiPTCwMlAxODV3IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
MCF7	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MYLHTVUxKD1iMD6wNFA2PSEQvF2=	MlHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
BT549	M{\OcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NIW4bXRIUTVyIE2gNE4xODB3NTFOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
UACC257	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NIj4V4lIUTVyIE2gNE4xODB3OTFOwG0>	M2rCNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
SF539	Mm\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MUnHTVUxKD1iMD6wNFA2QSEQvF2=	Moj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
HCC2998	NGPsOoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MkXUS2k2OCB;IECuNFAxPiEQvF2=	NGCwWpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
HCT116	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MUnHTVUxKD1iMD6wNFA3KM7:TR?=	Mn\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
T47D	NUK1SG9sT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NGTt[nVIUTVyIE2gNE4xODB4IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
CAKI-1	NUHXSVFKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NFW5[HpIUTVyIE2gNE4xODB4NjFOwG0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SK-MEL-5	NEO0SWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				Mn3JS2k2OCB;IECuNFAxPjhizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
RXF393	NIDqfWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MVPHTVUxKD1iMD6wNFA4OSEQvF2=	M2jQS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
LOXIMVI	M1v3NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MmnHS2k2OCB;IECuNFAxPzhizszN	Mo\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
ACHN	Mo[3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MlXrS2k2OCB;IECuNFAxPzlizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SR	NXWy[oFUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NWnBV4J5T0l3MDC9JFAvODByOEWg{txO	Mnq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
UACC62	NGfyfXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NGD4PHlIUTVyIE2gNE4xODB7MTFOwG0>	NXrh[\|I{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
M14	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M{DJUWdKPTBiPTCwMlAxODl\|IN88US=>	NYPY[I1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
HT-29	NFnMWnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M{PidWdKPTBiPTCwMlAxODl3IN88US=>	Mo\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
HOP92	NFPHdmxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NF3qUGdIUTVyIE2gNE4xODFizszN	MonUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
NCI-H23	M1mxXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MnftS2k2OCB;IECuNFAyKM7:TR?=	NH34c2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
TK10	MoXmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NGiybVJIUTVyIE2gNE4xODFizszN	M4O1UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
CEM	NFy0UnpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3rKdFczKGi{cx?=		M2fnU2dKPTBiPTCwMlAxOSEQvF2=	MoTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NEG1PFIoRjJ6NESxOVgzRC:jPh?=
U266	NWjRZo1sSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWW3NkBpenN?		M3Xt[WdKPTBiPTCwMlAxOSEQvF2=	NG\scm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES0NVU5Oid-Mki0OFE2QDJ:L3G+
Hs 578T	MkDSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NXrxT2o4T0l3MDC9JFAvODBzMEKg{txO	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
UO31	MnX4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MV\HTVUxKD1iMD6wNFExPSEQvF2=	MlyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SK-MEL-2	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				Ml7VS2k2OCB;IECuNFAyODdizszN	MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SN12C	MnLjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MWXHTVUxKD1iMD6wNFEyKM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
K562	NEHPTmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NH\1VHFIUTVyIE2gNE4xODFzNzFOwG0>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SF268	NHPCS2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NV3STmJCT0l3MDC9JFAvODBzMUeg{txO	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
COLO205	M{fyXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NY\UWWo{T0l3MDC9JFAvODBzMkOg{txO	NV\5S4pFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
MDA-MB-231	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MmDSS2k2OCB;IECuNFAyOjZizszN	NGfsO2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
NCI-H522	M3;uNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NI\RTY1IUTVyIE2gNE4xODF2NDFOwG0>	NXq1S3ZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
786-0	M{G5T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MUnHTVUxKD1iMD6wNFE1PCEQvF2=	NW\NOYZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
MDA-MB-468	M{XDVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MmTRS2k2OCB;IECuNFAyPDhizszN	MoO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
HCT15	NHPxeYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MYDHTVUxKD1iMD6wNFE2OSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
U251	M4qzbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MnHIS2k2OCB;IECuNFAyPTVizszN	M1j2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
OVCAR5	NGT1cotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MmTIS2k2OCB;IECuNFAyPTVizszN	M1Prb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
KM12	M2LMOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M1m1OWdKPTBiPTCwMlAxOTdizszN	MnnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SF295	MnjhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MXvHTVUxKD1iMD6wNFE4KM7:TR?=	M3;GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
DU145	MmjUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NUH2OGdTT0l3MDC9JFAvODBzNzFOwG0>	NUHlNGx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
HL-60(TB)	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M2jIRmdKPTBiPTCwMlAxOTlizszN	MojBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
OVCAR4	M375VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M2HN[GdKPTBiPTCwMlAxOTl3IN88US=>	MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SNB19	NHLTR49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NI\pbpFIUTVyIE2gNE4xODJyNDFOwG0>	M3jSV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
SNB75	M1XYbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MXzHTVUxKD1iMD6wNFIxPCEQvF2=	M2rsZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
IGROV1	MnHJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NXrpXnZ7T0l3MDC9JFAvODB{MkSg{txO	M3izUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
OVCAR8	Mlj6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MU\HTVUxKD1iMD6wNFI3OyEQvF2=	MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
PC3	NH64VVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NHXVWWxIUTVyIE2gNE4xODJ4MzFOwG0>	MnHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
EKVX	NXTzbJRNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MoHBS2k2OCB;IECuNFA{ODJizszN	NWD0NZYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
A549/ATCC	M3jmT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NUjTfoJVT0l3MDC9JFAvODB\|MEmg{txO	NHPMeZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
HOP62	M3rXNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MYHHTVUxKD1iMD6wNFQ1PyEQvF2=	NXPQVplWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
NCI-H460	MnrDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MWTHTVUxKD1iMD6wNFQ1PyEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
K562	NXTnVIhtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWrOZ3pTPzJiaILz		NEHVbmJIUTVyIE2gNE4xODdizszN	MkX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NEG1PFIoRjJ6NESxOVgzRC:jPh?=
NCI-ADR-RES	NGfPfnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M2\sTmdKPTBiPTCwMlAyOjNizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SKOV3	Mn3GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M{LIRmdKPTBiPTCwMlAyOzhizszN	MoL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
NCI-H322M	MlXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M3rIWGdKPTBiPTCwMlAyPzhizszN	NIOx[ng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
DLD1	NYrjN4FYTnWwY4Tpc44h[XO\|YYm=		NX65fJFNPiCqcoO=		MV\JR\|UxKD1iMD6wNFAzKM7:TR?=	MnrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{ME[4OlkoRjJ{MkC2PFY6RC:jPh?=
DLD1	NV;wNXhUTnWwY4Tpc44h[XO\|YYm=		Ml7nOkBpenN?		MWfJR\|UxKD1iMD6wNFA6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyNki2PUc,OjJ{ME[4Olk9N2F-
HCT116	MkDkR5l1d3SxeHnjbZR6KGG\|c3H5		M33aO\|czKGi{cx?=		MljUTWM2OCB;IECuNFAyKM7:TR?=	M3;VTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
HCT116	NEP5SIhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NYqxRm9NPzJiaILz		NI\qR5RKSzVyIE2gNE4xODF2IN88US=>	NWfGXIxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
HepG2	MljuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXraXnJxPzJiaILz		MoD2TWM2OCB;IECuNFAyPjFizszN	M3\DWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
SKOV3	M1\sWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mn3KO\|IhcHK\|		M{L2UGlEPTBiPTCwMlAxOTZ{IN88US=>	MlnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkmwN\|MoRjJ5N{[5NFM{RC:jPh?=
A2780	M1;YNGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NVnIbopKUUN3MDC9JFAvODBzNzFOwG0>	Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OFcoRjF6MkS3OVQ4RC:jPh?=
DOGUM	NUjGU4FFS3m2b4TvfIlkcXS7IHHzd4F6		M{f3W\|czKGi{cx?=		M1jNb2lEPTBiPTCwMlAxOiEQvF2=	M{i2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEOxOVkxLz5{M{CzNVU6ODxxYU6=
U266	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		MUe3NkBpenN?		MUXJR\|UxKD1iMD6wNFI1PSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|N{exOkc,OTl3M{e3NVY9N2F-
A549	MkPVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHPtfIE4OiCqcoO=		NFzzbIlKSzVyIE2gNE4xODJ3IN88US=>	MkLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOEK5PVAoRjJ6MUiyPVkxRC:jPh?=
HL60	M1LyUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYi3NkBpenN?		M1jpd2lEPTBiPTCwMlAxOzJizszN	MnvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOEK5PVAoRjJ6MUiyPVkxRC:jPh?=
RPMI18226	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		M1TmTFczKGi{cx?=		NF;QUZRKSzVyIE2gNE4xODN3IN88US=>	M4\6U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEe3OlgyLz5{MUC3O\|Y5OTxxYU6=
HL60	MorOR5l1d3SxeHnjbZR6KGG\|c3H5		NYD6PVhHPzJiaILz		NGHQXnNKSzVyIE2gNE4xODN3IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
RPMI8226	M3SyW2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M{Hpe\|czKGi{cx?=		MlzZTWM2OCB;IECuNFA{QDhizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4NUi2O{c,OjZ7NkW4Olc9N2F-
HL60	MUTGeY5kfGmxbjDhd5NigQ>?		MY[yJIhzew>?		NH73V\|FKSzVyIE2gNE4xODRizszN	M3;wWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
U266	NV7HNFNTTnWwY4Tpc44h[XO\|YYm=		NVrtSXliOSCqch?=		MV;JR\|UxKD1iMD6wNFQh\|ryP	MlLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NEG1PFIoRjJ6NESxOVgzRC:jPh?=
HL60	MnLuSpVv[3Srb36gZZN{[Xl?		MlHkNkBpenN?		M4rVXWlEPTBiPTCwMlAxPCEQvF2=	M1\5XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
SEM	MW\GeY5kfGmxbjDhd5NigQ>?		MWKyJIhzew>?		MknLTWM2OCB;IECuNFA1PDNizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
HL60	M1LkbWN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mn;UO\|IhcHK\|		M3W4dWlEPTBiPTCwMlAxPTVizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|N{exOkc,OTl3M{e3NVY9N2F-
U266	NG\OcVVEgXSxdH;4bYNqfHliYYPzZZk>		M{P0RVczKGi{cx?=		MkfVTWM2OCB;IECuNFA2PzNizszN	MkK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkW4OlcoRjJ4OU[1PFY4RC:jPh?=
MGC803	NWTFUWNpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUP0[2hKPzJiaILz		MknQTWM2OCB;IECuNFA2Pzh{IN88US=>	NFXudm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
GUMBUS	MmDER5l1d3SxeHnjbZR6KGG\|c3H5		MkHNO\|IhcHK\|		NHnhVVFKSzVyIE2gNE4xODZizszN	M1O2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEOxOVkxLz5{M{CzNVU6ODxxYU6=
ARH77	NV73WlVXS3m2b4TvfIlkcXS7IHHzd4F6		Mlv5O\|IhcHK\|		MXTJR\|UxKD1iMD6wNFYxPyEQvF2=	M1LYRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[1PFY4Lz5{Nkm2OVg3PzxxYU6=
SW480	NXj3dJoyS3m2b4TvfIlkcXS7IHHzd4F6		MVW3NkBpenN?		M{fpSmlEPTBiPTCwMlAxPjFizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
MDA-MB-231	MnjQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1uwfFczKGi{cx?=		MV;JR\|UxKD1iMD6wNFY2KM7:TR?=	NG\HTGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG4Nlk6OCd-MkixPFI6QTB:L3G+
HL60	Mn7hSpVv[3Srb36gZZN{[Xl?		NES2NnozKGi{cx?=		NIDQZ5pKSzVyIE2gNE4xODZ4NzFOwG0>	M{\LXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
A549	MkDWR5l1d3SxeHnjbZR6KGG\|c3H5		NW\CV2dyPzJiaILz		NXHsOHFmUUN3MDC9JFAvODB4NzFOwG0>	M{PhNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
RPMI8226	NEfhe4NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIiyTWE4OiCqcoO=		M363VmlEPTBiPTCwMlAxPjdizszN	NGTLXmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG4Nlk6OCd-MkixPFI6QTB:L3G+
5TGM1	NGr3fmREgXSxdH;4bYNqfHliYYPzZZk>		MUm0PEB1dyB5MjDodpM>		MoO2TWM2OCB;IECuNFA3PzhizszN	M2mzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5OVU6Lz5{NEGxPVU2QTxxYU6=
HL60	MmS5R5l1d3SxeHnjbZR6KGG\|c3H5		MkHtO\|IhcHK\|		MVLJR\|UxKD1iMD6wNFY6KM7:TR?=	NUDIem9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFc5OzJpPkG5O\|Q4QDN{PD;hQi=>
PC3	M2\JXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIX4fVY4OiCqcoO=		MY\JR\|UxKD1iMD6wNFch\|ryP	NXO2b\|hTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOVgyQDRpPkKwNVU5OTh2PD;hQi=>
DOGUM	NFvHUW5EgXSxdH;4bYNqfHliYYPzZZk>		M2LCV\|czKGi{cx?=		NXjwTHhQUUN3MDC9JFAvODB5IN88US=>	MkLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyM{G1PVAoRjJ\|MEOxOVkxRC:jPh?=
HL60	NIHiO4FEgXSxdH;4bYNqfHliYYPzZZk>		M2XVZVczKGi{cx?=		MV3JR\|UxKD1iMD6wNFcyKM7:TR?=	M13nd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
MKN45	MmDFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlXZO\|IhcHK\|		M4nFUmlEPTBiPTCwMlAxPzF3IN88US=>	MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkmwN\|MoRjJ5N{[5NFM{RC:jPh?=
HepG2	M2D1NWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHHVdGw4OiCqcoO=		NE[4XlFKSzVyIE2gNE4xODd3IN88US=>	MojiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
HL60	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF7lVoI4OiCqcoO=		NGn2O3lKSzVyIE2gNE4xODd4IN88US=>	Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkmwN\|MoRjJ5N{[5NFM{RC:jPh?=
RPMI8226	MVjDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6\|dDDoeY1idg>?		MUO3NkBpenN?		MkPmTWM2OCB;IECuNFA4QTZizszN	M3fWVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[3PFE5Lz5{NEe2O\|gyQDxxYU6=
HL60	NVTwVZAzS3m2b4TvfIlkcXS7IHHzd4F6		NV:5OFFCPzJiaILz		MYrJR\|UxKD1iMD6wNFgh\|ryP	MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
MGC803	M4XMbmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{HOWVczKGi{cx?=		NWC0UldZUUN3MDC9JFAvODB6IN88US=>	NHfDPJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[zOFA{QSd-Mki2N\|QxOzl:L3G+
SKOV3/TR	NXPqVJp1TnWwY4Tpc44h[XO\|YYm=		MlPVOEBl[Xm\|		MXvJR\|UxKD1iMD6wNFgh\|ryP	NFLYNXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe2O\|k4Oyd-Mkm3Olc6PzN:L3G+
PC3	MkWxR5l1d3SxeHnjbZR6KGG\|c3H5		MmHmO\|IhcHK\|		NYL2cINSUUN3MDC9JFAvODB6MzFOwG0>	NEH0cnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC3O\|Y5OSd-MkGwO\|c3QDF:L3G+
U266	M2\sVWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MknkO\|IhcHK\|		NYTNZXkzUUN3MDC9JFAvODB6ODFOwG0>	MnvCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
RPMI8226	M1;yVGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NEHON29KSzVyIE2gNE4xODh6IN88US=>	NY\l[oc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3Nlc4PDZpPkKwO\|I4PzR4PD;hQi=>
RPMI8226	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		MVy0PEB1dyB5MjDodpM>		M4HiO2lEPTBiPTCwMlAxQTVizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzOUW1PUc,OjRzMUm1OVk9N2F-
ARH77	M2fyPGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoXaO\|IhcHK\|		MoLOTWM2OCB;IECuNFA6PTdizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl\|NEKxPEc,Ojl7M{SyNVg9N2F-
HEK293	M3X2dGZ2dmO2aX;uJIF{e2G7		NVvX[G56OyCqcoO=		M2rqXGlEPTBiPTCwMlAyKM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUezPUc,OjB6N{W3N\|k9N2F-
HCT116	M{TMXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NF3UPG84OiCqcoO=		Mlu4TWM2OCB;IECuNFEh\|ryP	NWnNOXFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFc4PTdpPkKzOVQ4PzV5PD;hQi=>
NCI-H929	MmXVR5l1d3SxeHnjbZR6KGG\|c3H5		NIK5Z3I4OiCqcoO=		NVvhd\|ZLUUN3MDC9JFAvODFyOEWg{txO	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4N{ixPEc,OjR5Nke4NVg9N2F-
CCRF-CEM	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnfoO\|IhcHK\|		NYXwfm9lUUN3MDC9JFAvODFzIN88US=>	M{juSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVYzLz5{NkKzNVE3OjxxYU6=
RPMI8226	NUTL[XVbS3m2b4TvfIlkcXS7IHHzd4F6		M2jzOVczKGi{cx?=		NXriSVFFUUN3MDC9JFAvODFzMjFOwG0>	M3W0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUO0NlE5Lz5{OUmzOFIyQDxxYU6=
U266B1	NXz5TVR5S3m2b4TvfIlkcXS7IHHzd4F6		NEnZWHI4OiCqcoO=		NHizOIpKSzVyIE2gNE4xOTF4MzFOwG0>	MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7M{SyNVgoRjJ7OUO0NlE5RC:jPh?=
BxPC3	MmfER5l1d3SxeHnjbZR6KGG\|c3H5		MW[3NkBpenN?		NIfJ[nhKSzVyIE2gNE4xOTF6IN88US=>	NILKUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0O\|g{Oid-MUm3OFc5OzJ:L3G+
293T	M171d2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYCzSVBCPzJiaILz		NHTlTJFKSzVyIE2gNE4xOTJizszN	NF;GUWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5NVg2OCd-MkixPVE5PTB:L3G+
U266	MkTHR5l1d3SxeHnjbZR6KGG\|c3H5		MoTlO\|IhcHK\|		NUjxcno1UUN3MDC9JFAvODF{MjFOwG0>	NFzFfG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0O\|g{Oid-MUm3OFc5OzJ:L3G+
SW480	MoHoR5l1d3SxeHnjbZR6KGG\|c3H5		MYm3NkBpenN?		M2jZ[GlEPTBiPTCwMlAyOjNizszN	NWW1[2FwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwO\|c3QDFpPkKxNFc4PjhzPD;hQi=>
SKOV3	NIr6c\|ZEgXSxdH;4bYNqfHliYYPzZZk>		NF;2UFg1KGSjeYO=		M{DrNWlEPTBiPTCwMlAyOjlizszN	NVLpe5dURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3Olc6PzNpPkK5O\|Y4QTd\|PD;hQi=>
A549	M4TzOmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWfhTWxQPzJiaILz		MUDJR\|UxKD1iMD6wNVM6KM7:TR?=	MkP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyN{e2PFEoRjJzMEe3OlgyRC:jPh?=
HEK293	NWjXbY9mTnWwY4Tpc44h[XO\|YYm=		M3;FfFMxKG2rboO=		NVHuZYdoUUN3MDC9JFAvODF2IN88US=>	Mkf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyNES4OFcoRjJzMES0PFQ4RC:jPh?=
RPMI8266	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1LuPFczKGi{cx?=		NFvuU\|BKSzVyIE2gNE4xOTR2IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ\|MUG2Nkc,OjZ{M{GxOlI9N2F-
BxPC3	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MorsO\|IhcHK\|		MmDyTWM2OCB;IECuNFE3OiEQvF2=	M{TOb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
MDA-MB-231	NIXBTYxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVG3NkBpenN?		NY\HdFBnUUN3MDC9JFAvODF4NkWg{txO	M{\wV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
TOV21G	NFrCRmZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NYCxeYRwPzJiaILz		Mk\XTWM2OCB;IECuNFE3PyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ\|MUG2Nkc,OjZ{M{GxOlI9N2F-
MDA-MB-231	NH25XohEgXSxdH;4bYNqfHliYYPzZZk>		NHvHeZU4OiCqcoO=		MVnJR\|UxKD1iMD6wNVch\|ryP	NW\LcoxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2N\|QxOzlpPkK4OlM1ODN7PD;hQi=>
BxPC3	NVTBPIR4S3m2b4TvfIlkcXS7IHHzd4F6		NYfLUIhVPzJiaILz		MUHJR\|UxKD1iMD6wNVk1KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
HeLa	M3ntfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWC3NkBpenN?		NYW5XFRyUUN3MDC9JFAvODJizszN	NULVbI8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NlgzPDVpPkG5OFI5OjR3PD;hQi=>
RKO	NFjJbYlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlvXO\|IhcHK\|		NHHl[o5KSzVyIE2gNE4xOjB6IN88US=>	M{nyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVYzLz5{NkKzNVE3OjxxYU6=
MCF7	NGT3WGRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWGzJIRigXN?		NU\rfplDUUN3MDC9JFAvODJ3IN88US=>	Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N\|AoRjJ6NUW3OFMxRC:jPh?=
Bel7404	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlrFO\|IhcHK\|		M336VGlEPTBiPTCwMlAzPTB2IN88US=>	M1LP[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
HepG2	NE\EZXVEgXSxdH;4bYNqfHliYYPzZZk>		NWPzcnN3PzJiaILz		NF7q[I1KSzVyIE2gNE4xOjV{IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
HEK293	M3jtcGZ2dmO2aX;uJIF{e2G7		Mmm3NlQhcHK\|		MWXJR\|UxKD1iMD6wNlch\|ryP	M1\teVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFI6Lz5{MU[zOFQzQTxxYU6=
HCT116	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWW3NkBpenN?		NETuWZhKSzVyIE2gNE4xOjdizszN	MmTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOlIoRjJ4MkOxNVYzRC:jPh?=
SUP-B15	MW\GeY5kfGmxbjDhd5NigQ>?		NXO4Z\|JuOiCqcoO=		MXLJR\|UxKD1iMD6wNlgxQSEQvF2=	NIS0Tm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
A431	NYfFT4d3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M133XlczKGi{cx?=		NYXGdY9XUUN3MDC9JFAvODJ6MjFOwG0>	NGXEXJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN\|EyPjJ:L3G+
A2780	NXix[FJSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGDDVlU4OiCqcoO=		MVfJR\|UxKD1iMD6wNlg6KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF6Mkm5NEc,OjhzOEK5PVA9N2F-
HL60	MoHXSpVv[3Srb36gZZN{[Xl?		M4LsW\|IhcHK\|		NXu0TIZTUUN3MDC9JFAvODNizszN	NVv4V5lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
HL60	M2mxSGZ2dmO2aX;uJIF{e2G7		NXPjVFU5OiCqcoO=		MX7JR\|UxKD1iMD6wN{DPxE1?	M3;VTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
HEK293	NEfUOGhHfW6ldHnvckBie3OjeR?=		MYe2JIhzew>?		NYG5[4RRUUN3MDC9JFAvODNizszN	M17SUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG5N\|QxLz5{OEmxPVM1ODxxYU6=
WM266.4	MmG2R5l1d3SxeHnjbZR6KGG\|c3H5		NUHOVXJoPzJiaILz		MWXJR\|UxKD1iMD6wN\|Uh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyNki2PUc,OjJ{ME[4Olk9N2F-
GUMBUS	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		M13mN\|czKGi{cx?=		Ml3nTWM2OCB;IECuNFM2KM7:TR?=	NILqOXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CzNVU6OCd-MkOwN\|E2QTB:L3G+
HepG2	M3XUV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NX3OSZdFPzJiaILz		M4T2cWlEPTBiPTCwMlA{PzVizszN	Mk\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{e3NVYoRjF7NUO3O\|E3RC:jPh?=
95-D	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=		MlXvO\|IhcHK\|		MY\JR\|UxKD1iMD6wN\|gh\|ryP	MnLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
95-D	M4nPdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVy2fmdvPzJiaILz		NX:5fYZUUUN3MDC9JFAvODN6MUig{txO	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
SW480	MlfwR5l1d3SxeHnjbZR6KGG\|c3H5		NWLXN3ZlPzJiaILz		NE\JdG1KSzVyIE2gNE4xPSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|N{exOkc,OTl3M{e3NVY9N2F-
KB	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		NVXIb\|VQPzJiaILz		MmfETWM2OCB;IECuNFU6PSEQvF2=	Ml71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{e3NVYoRjF7NUO3O\|E3RC:jPh?=
SKOV3	Moq3R5l1d3SxeHnjbZR6KGG\|c3H5		NXrIWGVmPzJiaILz		MUDJR\|UxKD1iMD6wOlY5KM7:TR?=	NWDvZnR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwO\|c3QDFpPkKxNFc4PjhzPD;hQi=>
SW1990	NX;wVYR1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHPMNoc4OiCqcoO=		NHHufWhKSzVyIE2gNE4xPzlyNjFOwG0>	NH2zfm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
HeLa	NGr4[pdEgXSxdH;4bYNqfHliYYPzZZk>		NXj1eWhFPzJiaILz		M336dGlEPTBiPTCwMlA6OiEQvF2=	MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{e3NVYoRjF7NUO3O\|E3RC:jPh?=
A549	NFvPb4dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3HKc\|czKGi{cx?=		M4CzR2lEPTBiPTCwMlA6OiEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7MUi1NEc,OjhzOUG4OVA9N2F-
H460	NVnSUo9WS3m2b4TvfIlkcXS7IHHzd4F6		M1;TVVczKGi{cx?=		MX3JR\|UxKD1iMD6xNVUh\|ryP	M1OwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
SKOV3	M17YXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1nrW\|czKGi{cx?=		MUfJR\|UxKD1iMD6xN{DPxE1?	M4XlWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
SKOV3	MlnnR5l1d3SxeHnjbZR6KGG\|c3H5		MUG3NkBpenN?		NXTVcHNkUUN3MDC9JFAvOTVzIN88US=>	NIHH[FA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1PFE5PCd-MkCxOVgyQDR:L3G+
A549	M{PrdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXG3NkBpenN?		MVjJR\|UxKD1iMD6yOVUh\|ryP	NYjZXndGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|c4OTZpPkG5OVM4PzF4PD;hQi=>
HL60	MnzISpVv[3Srb36gZZN{[Xl?		MXKyJIhzew>?		M12xTGlEPTBiPTCwMlQ1KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
HL60	MX7GeY5kfGmxbjDhd5NigQ>?		NYfGOZVPOiCqcoO=		NGrHZpBKSzVyIE2gNE41PCEQvF2=	MnXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
H460	MnnWR5l1d3SxeHnjbZR6KGG\|c3H5		MVy3NkBpenN?		M4XOO2lEPTBiPTCwMlc5KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
BGC823	NXfzeo42S3m2b4TvfIlkcXS7IHHzd4F6		M1f2clczKGi{cx?=		M1uzfmlEPTBiPTCwMlg5KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|N{exOkc,OTl3M{e3NVY9N2F-
MCF7	MorDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV73bVFxPzJiaILz		MVLJR\|UxKD1iMUiuN\|ch\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{Nk[yPUc,Ojl2Mk[2Nlk9N2F-
A549	M4[4VGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mo\aO\|IhcHK\|		M17ZRWlEPTBiPTCyMlE{PTd\|IN88US=>	M1S3NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
A549	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		MXW3NkBpenN?		M3Gwd2lEPTBiPTCyMlE1KM7:TR?=	M3LV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
BGC823	M3fQcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGi3V4w4OiCqcoO=		M{Lw[mlEPTBiPTCyMlg6KM7:TR?=	NFzCXHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0O\|g{Oid-MUm3OFc5OzJ:L3G+
MDA-MB-231	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4CwSFczKGi{cx?=		MUXJR\|UxKD1iMz6xNlUh\|ryP	NIrIXYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyOlYzQSd-Mkm0NlY3Ojl:L3G+
BCG823	M{\KXmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUHHcJdRPzJiaILz		NXfVVY4{UUN3MDC9JFMvOjlizszN	NHfmcpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1PFE5PCd-MkCxOVgyQDR:L3G+
A549	M3\RZ2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWnDXYdmPzJiaILz		NG\VWJZKSzVyIE2gPU4{OThizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR{Nk[yPUc,Ojl2Mk[2Nlk9N2F-
Calu6	NGPPSnBEgXSxdH;4bYNqfHliYYPzZZk>		MXO3NkBpenN?		M1;nSmxEPTBiPTCwMlAxPjFizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUezPUc,OjB6N{W3N\|k9N2F-
HEK293T	NH3EU5ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkXrOFghcHK\|		M4Wz[WxEPTBiPTCwMlAyPiEQvF2=	M2fRZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OESzNVAxLz5{OUi0N\|ExODxxYU6=
LO2	NV\wWoFDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFHGTIQ1QCCqcoO=		Mn;4UGM2OCB;IECuN\|k5KM7:TR?=	NH7pZ3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi0N\|ExOCd-Mkm4OFMyODB:L3G+
NCI-H929	MmnpR5l1d3SxeHnjbZR6KGG\|c3H5		MUm0PEBpenN?		NEC3emJNTDVyIE2gNE4xODZ4IN88US=>	NFX6WI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
U266	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=		Mn;MOFghcHK\|		M3K1PWxFPTBiPTCwMlAyQCEQvF2=	NITvWo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
LCL	NE\OTnBEgXSxdH;4bYNqfHliYYPzZZk>		NIT0eVE1QCCqcoO=		NW\BbnV2VER3MDC9JFAvODJizszN	NGTpZos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
MDA-MB-468	NFKwSHZEgXSxdH;4bYNqfHliYYPzZZk>		NFTxfXE1QCCqcoO=		NFO3XGpNTDVyIE2gNE4xOzdizszN	MmTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
RD-ES	M{O2PWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MUG0PEBpenN?		NXPHU3BXVER3MDC9JFAvODRizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
WE68	M33iU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NX:4NWJ2PDhiaILz		NXTYSHdYVER3MDC9JFAvOSEQvF2=	Ml32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
IMR90	NGLofIJEgXSxdH;4bYNqfHliYYPzZZk>		MnmyOFghcHK\|		MnHBUGQ2OCB;IECuNVMh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
KGN	NGL1RXJEgXSxdH;4bYNqfHliYYPzZZk>		M3SwXFQ5KGi{cx?=		MoTsUGQ2OCB;IECuNVgh\|ryP	Mn\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
HNDF	NX\MN2FuS3m2b4TvfIlkcXS7IHHzd4F6		NGj0fZY1QCCqcoO=		MnHFUGQ2OCB;IECuOFgh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
MCF10A	NIHpWGFEgXSxdH;4bYNqfHliYYPzZZk>		NI\6boI1QCCqcoO=		MYHMSFUxKD1iMT61JO69VQ>?	MoTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
SKOV3	NHz4VJZEgXSxdH;4bYNqfHliYYPzZZk>		M4XmSFQ5KGi{cx?=		MVrMSFUxKD1iMT62JO69VQ>?	NVT2bWwzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
MCF7	MlnsR5l1d3SxeHnjbZR6KGG\|c3H5		Ml3XOFghcHK\|		MW\MSFUxKD1iOT64JO69VQ>?	NWfXOWdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
HL60	MUTGeY5kfGmxbjDhd5NigQ>?	MXOxNFAhdk1?			M1OxOGlvcGmkaYTpc44hd2ZiY3j5cY91enmyc3nuMYxqc2ViYXP0bZZqfHlib3[gdJJwfGWjc3;t[UBqdiCqdX3hckBJVDZyIHPlcIx{KGG2IEGwNEBvVQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NUe2Nkc,OTl4NUW3OlI9N2F-
HeLa	MkjPSpVv[3Srb36gZZN{[Xl?	NIjKWGY2KG6P	NEXKNpc5KGi{cx?=		MXLJcohq[mm2aX;uJI9nKHC{b4TlZZNwdWViYXP0bZZqfHliaX6gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZidXLpdZVqfGmwR{e2Wk1HVCC{ZYDvdpRmeiCuZY\lcEBifCB3IH7NJIFnfGW{IEigbJJ{KGK7IHz1Z4ln\XKjc3WgZZN{[Xl?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF6Nke5OEc,OjFzOE[3PVQ9N2F-
HeLa	NWf2cWpuTnWwY4Tpc44h[XO\|YYm=	MUexJJVO	M{nEVVghcHK\|		M1y0[GlvcGmkaYTpc44hd2ZicILveIVie2:vZTDhZ5Rqfmm2eTDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjD1ZolyfWm2aX7HO\|ZXNU[OIILldI9zfGW{IHzleoVtKGG2IEGgeW0h[W[2ZYKgPEBpenNiYomgcJVkcW[ncnHz[UBie3OjeR?=	NIjPSFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG4Olc6PCd-MkGxPFY4QTR:L3G+
LN229	NXy4Rm5GTnWwY4Tpc44h[XO\|YYm=	NW\UXJhKOTByIH7N	MWixJIhz		NYLa[olMUW6qaXLpeIlwdiCxZjDITWYy[WyyaHGg[ZhxemW\|c3nvckBqdiCqdX3hckBNVjJ{OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhUEmILUHhcJBp[SCjY3P1cZVt[XSrb36gZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiC3bnTldkBvd3Kvb4jpZUBkd26maYTpc44h\m:ubH;3[YQh[nliMkSgbJJ{KGmwY4XiZZRqd25idX7k[ZIhcHmyb4jpZUBkd26maYTpc44h[nliV3XzeIVzdiCkbH;0eIlv\w>?	MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6M{G2N\|goRjJzOEOxOlM5RC:jPh?=
LN229	M13tXmZ2dmO2aX;uJIF{e2G7	M2XsTFIxKHWP	MXyxJIhz		M4Lpb2lvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkHhcJBp[SCjY3P1cZVt[XSrb36gbY4hcHWvYX6gUG4zOjliY3XscJMh[XRiMkCgeW0h[W[2ZYKgNUBpeiCycnXpcoN2[mG2aX;uJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NXTuZpVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwN\|I3OzJpPkKyNFMzPjN{PD;hQi=>
U1	MYrGeY5kfGmxbjDhd5NigQ>?	NIDwV\|IyOCC3TR?=	MUOyOEBpeg>?		M1\0e2lvcGmkaYTpc44hd2ZiTl[tb4FxeGGELX3l[IlifGWmII\pdoFtKHKncHzpZ4F1cW:wIHnuJGhwdW9ic3HwbYVveyBqaIXtZY4qKFVzIHPlcIx{KGmwZnXjeIVlKHerdHigXFQhfHKxcHnjJGhKXjFiTly0MVMh[XRiMUCgeW0h[W[2ZYKgNlQhcHJiYomgVnQuWEOUIHHuZYx6e2m\|IHnuJJBz\XOnbnPlJI9nKFSQRj3hcJBp[Q>?	MnH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OUCwOVEoRjJ\|MkmwNFUyRC:jPh?=
Calu6	NYXuc5NuTnWwY4Tpc44h[XO\|YYm=	MYixNEB2VQ>?	NFjPW4IyQCCqcoO=		Mlv6TY5pcWKrdHnvckBw\iCKaYOteIFo\2WmIF\yZZRigGmwIDj1cotvd3ewIH;ybYdqdilxVXLpdZVqfGmwIHnueIVz[WO2aX;uJIV5eHKnc4Pl[EBqdiCqdX3hckBE[Wy3NjDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBnemG2YYjpckApOS1{MUCpJJBz\WO3coPvdkBt\X[nbDDheEAyOCC3TTDh[pRmeiBzODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>?	NH7POpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WwOlQ5Pid-MkO1NFY1QDZ:L3G+
HCT116	NF\W[3NHfW6ldHnvckBie3OjeR?=				NWLhSnhUUW6qaXLpeIlwdiCxZjDwdo91\WG\|b33lJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44hd2ZicEWzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	NVzRe5RJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFc4PTdpPkKzOVQ4PzV5PD;hQi=>
HCT116	MWDBdI9xfG:\|aYOgZZN{[Xl?				MVjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiUFHSVEBkdGWjdnHn[UBjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{	M2DFSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUS3O\|U4Lz5{M{W0O\|c2PzxxYU6=
HCT116	MXPD[YxtKGO7Y3zlJIF{e2G7		MWOyOEBpenN?		NUjCXIQyS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpdy=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2N{e1O{c,OjN3NEe3OVc9N2F-
HEK293	NIjWWYpEgXSxdH;4bYNqfHliYYPzZZk>	NYPtS204OC5yMECxJJVOKHSxIEGwNEB2VQ>?	MkfwOFghcHK\|		MlixR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGVMOjl\|IHPlcIx{KGW6cILld5NqdmdibYXybY5mKE[DUDDheEAxNjByMEGgeW0hfG9iMUCwJJVOKGGodHXyJFQ5KGi{czDifUBE\WyuVHn0[ZIuSmy3ZTDhd5NigQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NEK3NUc,OjN3OUSyO\|E9N2F-
A549	MXHGeY5kfGmxbjDhd5NigQ>?	Mn7QNE4xOjVidH:gNE42KHWP	NXTDPI1xOjRiaILz		MVrJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjDwc4x6NXWkaYH1bZRqdmG2ZXSgdJJwfGWrboOgZZQhOC5yMkWgeI8hOC53IIXNJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0JIF{e2G7	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|OUi2Nkc,OjV4M{m4OlI9N2F-
A549	NF;xSW9HfW6ldHnvckBie3OjeR?=	MVewMlAzPSC2bzCwMlUhfU1?	NWn6dG9UOjRiaILz		MWXJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJJN1[WKrbHn6ZZRqd25ib3[gdFU{KGG2IECuNFI2KHSxIECuOUB2VSCjZoTldkAzPCCqcoOgZpkhcW2vdX7vZoxwfCCjc4PhfS=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|OUi2Nkc,OjV4M{m4OlI9N2F-
A549	MVjGeY5kfGmxbjDhd5NigQ>?	M2LmVVAvODJ3IITvJFAvOSC3TR?=	MlH0NlQhcHK\|		MWnJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjDOc5hiKGG2IECuNFI2KHSxIECuNUB2VSCjZoTldkAzPCCqcoOgZpkhcW2vdX7vZoxwfCCjc4PhfS=>	M{TZS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO5PFYzLz5{NU[zPVg3OjxxYU6=
AMO1	MlPIRY51cXS3bX;yJIF{e2G7	NUftWXlCOSCvZz;r[y=>			NVX6N\|Q1SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRW1QOSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueYRmKFOFSVSgZoVq\2VibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMTDt[{9s\yxiaY[gZYRucW6rc4TldoVlKHS5aXPlJJBmeiC5ZXXr	M{nDRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[1OlY3Lz5{NkW2OVY3PjxxYU6=
MCF7	MVjGeY5kfGmxbjDhd5NigQ>?	MVOzOUBvVQ>?	M3\UPFQhcHK\|		NIDLT5FKdmirYnn0bY9vKG:oIEK2V{Bxem:2ZXHzc41mKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKG:oIHjp[4ghdW:uZXP1cIFzKHenaXfoeEBxd2y7dXLpdZVqfGmwLXPvcop2\2G2ZXSgdJJwfGWrboOgZZQhOzVibl2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	M4C0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M1Lz5{N{m5OFc{PDxxYU6=
MDA-MB-468	M131OWZ2dmO2aX;uJIF{e2G7	NX\HN\|E{OzVibl2=	NGjPNG01KGi{cx?=		M{TvTWlvcGmkaYTpc44hd2ZiMk\TJJBzd3SnYYPvcYUhcW5iaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4YhcGmpaDDtc4xm[3WuYYKge4Vq\2i2IIDvcJl2[mmzdXn0bY4u[2:waoXnZZRm\CCycn;0[YlveyCjdDCzOUBvVSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NXjseoNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
MDA-MB-231	MnrqSpVv[3Srb36gZZN{[Xl?	M13sV\|EhfU1?			M2HnTmlvcGmkaYTpc44hd2ZidIL5dJNqdiCuaXvlJIFkfGm4aYT5JI9nKDJ4UzDwdo91\WG\|b33lJIRmemm4ZXSg[pJwdSCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF1KDFidV2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ7MUO0OEc,Ojh{OUGzOFQ9N2F-
MDA-MB-231	NIfMPWFHfW6ldHnvckBie3OjeR?=	MoLhNUB2VQ>?			NHnoTGRKdmirYnn0bY9vKG:oIHPhd5Bie2VibHnr[UBi[3Srdnn0fUBw\iB{NmOgdJJwfGWjc3;t[UBl\XKrdnXkJIZzd21iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BifCBzIIXN	M2LuWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkmxN\|Q1Lz5{OEK5NVM1PDxxYU6=
MDA-MB-231	NX;uTo5KTnWwY4Tpc44h[XO\|YYm=	NITtdVAyKHWP			NF3Gdm9KdmirYnn0bY9vKG:oIHPofY1wfHK7cIPpckBtcWunIHHjeIl3cXS7IH;mJFI3WyCycn;0[YF{d22nIHTldol3\WRiZoLvcUBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFEhfU1?	NUPCdWprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPVE{PDRpPkK4NlkyOzR2PD;hQi=>
SK-N-SH	NV3lSm1XS3m2b4TvfIlkcXS7IHHzd4F6	Ml7BNE4yKHSxIEGgeW0>	MmHENlQhcHK\|		MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNVOKIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEAxNjFidH:gNUB2VSCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6	NUn3ToN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOlkzPTVpPkK5NlY6OjV3PD;hQi=>
MYCN2	MWHDfZRwfG:6aXPpeJkh[XO\|YYm=	NXO3cpIyOC5zIITvJFEhfU1?	M4LFT\|I1KGi{cx?=		MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNXWNPOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgNE4yKHSxIEGgeW0h[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfS=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ4OUK1OUc,Ojl{NkmyOVU9N2F-
U266	M4riSmFxd3C2b4Ppd{Bie3OjeR?=	NX\rU49NOi53IH7N	M3TEd\|I1KGi{cx?=		M{H0Wmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iVUK2OkBk\WyuczDheEAzNjVibl2gZYZ1\XJiMkSgbJJ{KGK7IFHucoV5cW5iVj;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTNyNEK4OEc,Ojl\|MESyPFQ9N2F-
RPMI8226	M4O3PWFxd3C2b4Ppd{Bie3OjeR?=	NXnCOmpwOi53IH7N	MkniNlQhcHK\|		MojzTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCUUF3JPFIzPiClZXzsd{BifCB{LkWgcm0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJ6	NUfSSHpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNFQzQDRpPkK5N\|A1Ojh2PD;hQi=>
NCI-H929	NH\pepFCeG:ydH;zbZMh[XO\|YYm=	NGTzdIszNjVibl2=	NEXpcYQzPCCqcoO=		NFXneHZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JQTJ7IHPlcIx{KGG2IEKuOUBvVSCjZoTldkAzPCCqcoOgZpkhSW6wZYjpckBXN3C{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSg[oxwfyCleYTvcYV1enl?	NUTYdlNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNFQzQDRpPkK5N\|A1Ojh2PD;hQi=>
TC32	M4rlN5FJXFNiYYPzZZk>				NXPmfHhVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIO=	M3PXW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	Ml3jdWhVWyCjc4PhfS=>				NH7s[W5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz	NY\DNZhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M2\uZZFJXFNiYYPzZZk>				MkLLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	NX;Vc\|RFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	Mm\KdWhVWyCjc4PhfS=>				Mkm0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NIjpflA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NV7jPYtMeUiWUzDhd5NigQ>?				NGnNZ\|FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NW\odZdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NWnkOWkyeUiWUzDhd5NigQ>?				NV\vXJdFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NI\qfI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NHP6d5ZyUFSVIHHzd4F6				MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NIDYSHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NVvVPZJbeUiWUzDhd5NigQ>?				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	M13x[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	Mo\odWhVWyCjc4PhfS=>				NGfjUYhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	MoHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MonndWhVWyCjc4PhfS=>				NYWyV4c3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	M1ixU5FJXFNiYYPzZZk>				NHnZR4lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NVzHd2dTeUiWUzDhd5NigQ>?				NHHTSVhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	M1q3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MnrZdWhVWyCjc4PhfS=>				M3XxUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	NXTlcIp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast	NWH5O\|FYeUiWUzDhd5NigQ>?				Mn;KdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKGOxboTyc4whUGhid3ns[EB1gXCnIH\pZpJw[myjc4SgZ4VtdHN?	NHvJRoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NWrXXo53eUiWUzDhd5NigQ>?				NFHLVIFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	M1mzOpFJXFNiYYPzZZk>				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz	M2\CbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NIX5cVRyUFSVIHHzd4F6				M4W1fpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN?	Ml;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NFGxcplyUFSVIHHzd4F6				MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NF7wbFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MoDEdWhVWyCjc4PhfS=>				MlnYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	NF7RRYNyUFSVIHHzd4F6				NX;sPWo6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoN\|Ah[2WubIO=	NGXlcpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MWDxTHRUKGG\|c3H5				NELlSlJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	NHLJeHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	Mn;idWhVWyCjc4PhfS=>				M1vhdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	M{XK[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MUPxTHRUKGG\|c3H5				NE\5[WJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NYnBXYR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NX\hcmQxeUiWUzDhd5NigQ>?				MlPkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	NEmyS3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
fibroblast	M3PWc5FJXFNiYYPzZZk>				NX\uTnNxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	Ml;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NVLiNYp6eUiWUzDhd5NigQ>?				NIXBS2FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	NHHmfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M{nNVJFJXFNiYYPzZZk>				M2jST5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>?	M2HrflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MoizdWhVWyCjc4PhfS=>				NXLEVIlieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M{PWO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MXHxTHRUKGG\|c3H5				M{mwdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M{X1b5FJXFNiYYPzZZk>				NUi1PY45eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM>	MkWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Daoy	Mlj2dWhVWyCjc4PhfS=>				NVjSV206eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCGYX;5JINmdGy\|	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	M{XadJFJXFNiYYPzZZk>				M2\aTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1SgZ4F{eGG\|ZTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NE\sU2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MlzYdWhVWyCjc4PhfS=>				MoSydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NUG3PIJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	M4HwRZFJXFNiYYPzZZk>				NH7Qd5RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NWP2dmZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MkX6dWhVWyCjc4PhfS=>				Mnf4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NFPOZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	M4TXeJFJXFNiYYPzZZk>				Mn;idWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MmC1dWhVWyCjc4PhfS=>				NF\LTGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NIr1bFVyUFSVIHHzd4F6				Mn3IdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MkT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MoLwdWhVWyCjc4PhfS=>				M4mxO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	M{nGbJFJXFNiYYPzZZk>				MlfHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	M{HOSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NHXLdJlyUFSVIHHzd4F6				M4fjZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	MkfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M3j2T5FJXFNiYYPzZZk>				MlS5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	MoLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	M{TWb5FJXFNiYYPzZZk>				NUD0RWxUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	NHTsR4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	Ml;qdWhVWyCjc4PhfS=>				NXXQeJd{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	M1rvc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NXvidmxQeUiWUzDhd5NigQ>?				NHrUOYVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	NIq5eJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NEnhO3VyUFSVIHHzd4F6				MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN?	M3XnUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MY\xTHRUKGG\|c3H5				NIHUVpJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{	NH\oUHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HL60	NGLRWpJHfW6ldHnvckBie3OjeR?=	NIfQSZEyKHSxIEGwNEBvVQ>?	M17sV\|I1KGi{cx?=		NYLIVpY{UW6qaXLpeIlwdiCxZjDwdo91\WG\|b33lJIlvKGi3bXHuJGhNPjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ4xm[X[nZDDQRXJRKGW6cILld5Nqd25iYYSgNUB1dyBzMECgcm0h[W[2ZYKgNlQhcHK\|IHL5JIludXWwb3Lsc5Qh[XO\|YYm=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SUP-B15	MoDtSpVv[3Srb36gZZN{[Xl?	MYWxJJRwKDFyMDDuUS=>	NUjKdXpMOjRiaILz		MmPwTY5pcWKrdHnvckBw\iCycn;0[YF{d22nIHnuJIlu[XSrbnniMZJme2m\|dHHueEBpfW2jbjDTWXAuSjF3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJINt\WG4ZXSgVGFTWCCneIDy[ZN{cW:wIHH0JFEhfG9iMUCwJI5OKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91KGG\|c3H5	NITaPJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
SEM	MYPGeY5kfGmxbjDhd5NigQ>?	MmCxNUB1dyBzMECgcm0>	M3Xz[\|I1KGi{cx?=		MVjJcohq[mm2aX;uJI9nKHC{b4TlZZNwdWViaX6gbJVu[W5iU1XNJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGOuZXH2[YQhWEGUUDDlfJBz\XO\|aX;uJIF1KDFidH:gNVAxKG6PIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHzd4F6	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
SEM	NIK0XVhHfW6ldHnvckBie3OjeR?=	M3W2T\|ExKG6P	MnvkNVghcHK\|		MmDQTY5pcWKrdHnvckBw\iCycn;0[YF{d22nIHnuJIh2dWGwIGPFUUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZ3fy[ZNwdWViYXPjeY12dGG2aX;uJIF1KDFyIH7NJIFnfGW{IEG4JIhzeyCkeTDifUBHSUOVIHHuZYx6e2m\|	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SEM	MlfaSpVv[3Srb36gZZN{[Xl?	NFixS2gyOCCwTR?=	NEC4dIIyQCCqcoO=		Mor5TY5pcWKrdHnvckBw\iCycn;0[YF{d22nIHnuJIh2dWGwIGPFUUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZ3fy[ZNwdWViYXPjeY12dGG2aX;uJIF1KDFyIH7NJIFnfGW{IEG4JIhzeyCkeTDmcJVwemW\|Y3XuZ4UhdWmlcn;zZ49xcWNibXX0bI9l	M17EflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
HepG2	NYmz[m9yS2WubDD2bYFjcWyrdImgZZN{[Xl?				MYnI[ZBIOiClZXzsd{B3cWGkaXzpeJkheUiWUzDmc5IhYmmtYTD2bZJ2eyCrbnjpZol1d3K\|	NYHu[VVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{OyNlk2PDVpPkOzNlI6PTR3PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

In vivo

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

Protocol

Kinase Assay: ^[4]	- Collapse Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research: ^[5]	- Collapse Cell lines: Human multiple myeloma cells line U266 Concentrations: ~10 μM Incubation Time: 2 days Method: The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Human plasmacytoma xenografts RPMI 8226 Dosages: 1 mg/kg Administration: i.v. twice weekly for 4 weeks, then once weekly (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bortezomib (PS-341) SDF

Molecular Weight	384.24
Formula	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	LDP-341, MLM341
Smiles	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04656951	Not yet recruiting	Drug: Daratumumab	Multiple Myeloma	University of Cologne\|Janssen-Cilag G.m.b.H	January 2021	Phase 2
NCT04570631	Recruiting	Drug: Eftozanermin alfa\|Drug: Bortezomib\|Drug: Dexamethasone	Multiple Myeloma	AbbVie	November 5 2020	Phase 1
NCT03993262	Recruiting	Drug: Bortezomib\|Drug: Placebo	Autoimmune Encephalitis	Jena University Hospital	May 13 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Answer:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.
Classic Proteasome Inhibitor

ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Marimastat (BB-2516) ^New

Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Ixazomib (MLN2238)

Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
ONX-0914 (PR-957)

ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).
Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol

Celastrol (Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)